<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Appetite stimulants for people with cystic fibrosis - McTavish, D - 2022 | Cochrane Library</title> <meta content="Appetite stimulants for people with cystic fibrosis - McTavish, D - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008190.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Appetite stimulants for people with cystic fibrosis - McTavish, D - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008190.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008190.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Appetite stimulants for people with cystic fibrosis" name="citation_title"/> <meta content="Diane McTavish" name="citation_author"/> <meta content="Queen Elizabeth University Hospital" name="citation_author_institution"/> <meta content="diane.mctavish@ggc.scot.nhs.uk" name="citation_author_email"/> <meta content="Judith Thornton" name="citation_author"/> <meta content="National Institute for Health and Care Excellence" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD008190.pub3" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/09/23" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008190.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008190.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008190.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anorexia [chemically induced, drug therapy]; Anti-Bacterial Agents [therapeutic use]; Appetite Stimulants [therapeutic use]; Cyproheptadine [therapeutic use]; *Cystic Fibrosis [complications, drug therapy, genetics]; Megestrol Acetate [therapeutic use]; Quality of Life" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008190.pub3&amp;doi=10.1002/14651858.CD008190.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008190.pub3&amp;doi=10.1002/14651858.CD008190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008190.pub3&amp;doi=10.1002/14651858.CD008190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008190.pub3&amp;doi=10.1002/14651858.CD008190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008190.pub3&amp;doi=10.1002/14651858.CD008190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008190.pub3&amp;doi=10.1002/14651858.CD008190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008190.pub3&amp;doi=10.1002/14651858.CD008190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008190.pub3&amp;doi=10.1002/14651858.CD008190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008190.pub3&amp;doi=10.1002/14651858.CD008190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008190.pub3&amp;doi=10.1002/14651858.CD008190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008190.pub3&amp;doi=10.1002/14651858.CD008190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008190.pub3&amp;doi=10.1002/14651858.CD008190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008190.pub3&amp;doi=10.1002/14651858.CD008190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008190.pub3&amp;doi=10.1002/14651858.CD008190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008190.pub3&amp;doi=10.1002/14651858.CD008190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008190.pub3&amp;doi=10.1002/14651858.CD008190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008190.pub3&amp;doi=10.1002/14651858.CD008190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008190.pub3&amp;doi=10.1002/14651858.CD008190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008190.pub3&amp;doi=10.1002/14651858.CD008190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008190.pub3&amp;doi=10.1002/14651858.CD008190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008190.pub3&amp;doi=10.1002/14651858.CD008190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008190.pub3&amp;doi=10.1002/14651858.CD008190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008190.pub3&amp;doi=10.1002/14651858.CD008190.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="xNbeAU8n";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008190\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008190\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008190\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008190\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ko","pt","ms","fa","fr","hu"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008190.pub3",title:"Appetite stimulants for people with cystic fibrosis",firstPublishedDate:"Sep 23, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xNbeAU8n&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008190.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008190.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008190.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008190.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008190.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008190.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008190.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008190.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008190.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008190.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1515 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008190.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008190.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008190.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008190.pub3/full#CD008190-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008190.pub3/full#CD008190-sec-0100"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008190.pub3/full#CD008190-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008190.pub3/full#CD008190-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008190.pub3/full#CD008190-sec-0030"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008190.pub3/full#CD008190-sec-0031"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008190.pub3/full#CD008190-sec-0055"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008190.pub3/full#CD008190-sec-0091"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008190.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008190.pub3/appendices#CD008190-sec-0107"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008190.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008190.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/supinfo/CD008190StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/supinfo/CD008190StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008190.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008190.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008190.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008190.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008190.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008190.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Appetite stimulants for people with cystic fibrosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008190.pub3/information#CD008190-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Diane McTavish</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008190.pub3/information#CD008190-cr-0005">Judith Thornton</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/information/en#CD008190-sec-0115">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 23 September 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008190.pub3">https://doi.org/10.1002/14651858.CD008190.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008190-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008190-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008190-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008190-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008190-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008190-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD008190-abs-0009">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008190-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008190-abs-0001" lang="en"> <section id="CD008190-sec-0001"> <h3 class="title" id="CD008190-sec-0001">Background</h3> <p>Chronic loss of appetite in cystic fibrosis concerns both individuals and families. Appetite stimulants have been used to help cystic fibrosis patients with chronic anorexia attain optimal body mass index (BMI) and nutritional status. However, these may have adverse effects on clinical status. This is an updated version of the original review. </p> </section> <section id="CD008190-sec-0002"> <h3 class="title" id="CD008190-sec-0002">Objectives</h3> <p>To systematically search for and evaluate the evidence on the beneficial effects of appetite stimulants in the management of cystic fibrosis‐related anorexia and synthesise reports of any side effects. </p> </section> <section id="CD008190-sec-0003"> <h3 class="title" id="CD008190-sec-0003">Search methods</h3> <p>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Cystic Fibrosis Trials Register and online trials registries; handsearched reference lists; and contacted local and international experts to identify relevant trials. </p> <p>Last search of the Cystic Fibrosis Trials Register: 23 May 2022.</p> <p>Last search of online trial registries: 10 May 2022.</p> </section> <section id="CD008190-sec-0004"> <h3 class="title" id="CD008190-sec-0004">Selection criteria</h3> <p>Randomised and quasi‐randomised controlled trials of appetite stimulants compared to placebo, control, no treatment or different appetite stimulants, or to the same appetite stimulants at different doses or regimens for at least one month in adults and children with cystic fibrosis. </p> </section> <section id="CD008190-sec-0005"> <h3 class="title" id="CD008190-sec-0005">Data collection and analysis</h3> <p>Review authors independently extracted data and assessed risk of bias of the included trials. We used the GRADE approach to assess the certainty of the evidence and performed meta‐analyses. </p> </section> <section id="CD008190-sec-0006"> <h3 class="title" id="CD008190-sec-0006">Main results</h3> <p>We included four trials (70 participants) comparing appetite stimulants (cyproheptadine hydrochloride and megestrol acetate) to placebo; the numbers of adults or children within each trial were not always reported. We assessed the certainty of evidence as low due to the small number of participants, incomplete or selective outcome reporting, and unclear risk of selection bias.  </p> <p>Regarding our primary outcomes, a meta‐analysis of two trials (42 participants) showed that appetite stimulants may produce a larger increase in weight (kg) at three months (mean difference (MD) 1.25 kg, 95% confidence interval (Cl) 0.45 to 2.05), and one trial (17 participants) showed a similar result at six months (MD 3.80 kg, 95% CI 1.27 to 6.33) (both low‐certainty evidence). Results also showed that weight z score may increase with appetite stimulants compared to placebo at three months (MD 0.61, 95% CI 0.29 to 0.93; 3 studies; 40 participants; P &lt; 0.001) and at six months (MD 0.74, 95% CI 0.26 to 1.22; 1 trial; 17 participants). There was no evidence of a difference in effect between cyproheptadine hydrochloride and megestrol acetate for either outcome.   </p> <p>Only one trial (25 participants) reported analysable data for body composition (BMI), with results favouring cyproheptadine hydrochloride compared to placebo; a further trial (16 participants) narratively agreed with this result. </p> <p>All four trials reported on lung function at durations ranging from two to nine months. Considering analysable data, two trials (42 participants) found that appetite stimulants may make little or no difference in forced expiratory volume at one second (FEV<sub>1</sub>) % predicted at three months, and one trial (17 participants) found similar results at six months. Two further three‐month trials narratively agreed with these results. </p> <p>Limited information was reported for secondary outcomes. Two trials (23 participants) reported results showing that appetite stimulants may increase appetite compared to placebo at three months (odds ratio 45.25, 95% CI 3.57 to 573.33; low‐certainty evidence).  </p> <p>Only one study reported on quality of life, finding that cyproheptadine reduced fatigue in two participants compared with none with placebo. One study (25 participants) found no difference in energy intake between appetite stimulant or placebo at three months. Insufficient reporting of adverse effects prevented a full determination of their impact. Two studies (33 participants) narratively reported similar requirements for additional antibiotics between appetite stimulants and placebo at three months.  </p> </section> <section id="CD008190-sec-0007"> <h3 class="title" id="CD008190-sec-0007">Authors' conclusions</h3> <p>At six months in adults and children, appetite stimulants improved only two of the outcomes of this review: weight (or weight z score) and subjectively reported appetite. Insufficient reporting of side effects prevented a full determination of their impact. Whilst the data may suggest the potential use of appetite stimulants in treating anorexia in adults and children with cystic fibrosis, this is based upon low‐certainty evidence from a small number of trials, therefore firm conclusions cannot be drawn. Clinicians need to be aware of the potential adverse effects of appetite stimulants and actively monitor any individuals prescribed these medications accordingly. </p> <p>Research is required to determine meaningful surrogate measures for appetite and to define what constitutes quality weight gain. Future trials of appetite stimulants should use a validated measure of symptoms including a disease‐specific instrument for measuring poor appetite. This review highlights the need for multicentred, adequately powered, and well‐designed trials to evaluate agents to safely increase appetite in people with cystic fibrosis and to establish the optimal mode of treatment. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008190-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008190-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008190-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008190-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008190-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/hu#CD008190-abs-0016">Magyar</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008190-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008190-abs-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD008190-abs-0010">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD008190-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008190-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD008190-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008190-abs-0002" lang="en"> <h3>Appetite stimulants for people with cystic fibrosis</h3> <p><b>Review question</b> </p> <p>We looked for evidence on both beneficial and adverse effects of using appetite stimulants in people with anorexia linked to cystic fibrosis. </p> <p><b>Background</b> </p> <p>Loss of appetite in people with cystic fibrosis concerns both those with the disease and their families. Appetite stimulants have been used to help people with cystic fibrosis who have a poor appetite to increase the amounts they eat so they gain weight and improve their overall health. However, there are concerns that appetite stimulants can cause side effects. This is an updated version of the original review. </p> <p><b>Search date</b> </p> <p>We last looked for evidence on 23 May 2022.</p> <p><b>Study characteristics</b> </p> <p>We included four trials (70 participants), two of which were performed in children and two in both children and adults. The trials looked at the effects of drugs (megestrol acetate and cyproheptadine hydrochloride) compared to a placebo (a tablet that contained no medicine) to stimulate appetite. The trials lasted between three and six months. </p> <p><b>Key results</b> </p> <p>We found that these drugs may improve weight and appetite in the short term (up to six months). No effect was seen on lung function. All stimulants can have adverse effects which can worsen cystic fibrosis, such as effects on blood sugar control, fatigue, mood, fluid retention, the liver, and shortness of breath, but unfortunately insufficient reporting of side effects prevented a full understanding of their effects. The included trials were too small to show if megestrol acetate and cyproheptadine hydrochloride can improve weight and appetite safely. </p> <p>Whilst there is evidence to suggest that appetite stimulants may improve weight and poor appetite in adults and children with cystic fibrosis, we believe more research is needed to identify appropriate ways of measuring appetite, and then to collect sound data from enough patients to find out if appetite stimulants can improve appetite safely in cystic fibrosis. </p> <p><b>Certainty of the evidence</b> </p> <p>We have low confidence in the results being able to show the true effectiveness of appetite stimulants. We came to this conclusion because although we think that most of the people taking part had the same chance of being in the appetite stimulant or placebo group, and no one could not tell the difference between the appetite stimulant or the placebo, there may be some bias due to the small numbers of participants in the studies, and because in two studies some participants withdrew without clear reasons being given. Another possible source of bias is that three studies did not report on all of their pre‐planned outcomes.  </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008190-sec-0100" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008190-sec-0100"></div> <h3 class="title" id="CD008190-sec-0101">Implications for practice</h3> <section id="CD008190-sec-0101"> <p>The data included in this review suggest that megestrol acetate (MA) and cyproheptadine hydrochloride (CH) may be useful for short‐term (i.e. six months) treatment of anorexia in adults and children with cystic fibrosis (CF). However, we cannot conclude whether any one stimulant is more effective than another. Based on the included randomised controlled trials (RCTs) and the meta‐analyses, we are unable to suggest an optimal dosage, duration, or timing of appetite stimulant therapy. Furthermore, if cost and availability of the agents are compared, MA prescribed at 160 mg once per day costs GBP 19.52 for 30 tablets (<a href="./references#CD008190-bbs2-0120" title="Joint Formulary Committee. British National Formulary No 82. Pharmaceutical Press, 2021. [ISBN: 9780857114136]">BNF 2021</a>), but the most cost‐competitive agent is CH: 4 mg tablets prescribed once per day at a cost of GBP 5.99 for 30 tablets (<a href="./references#CD008190-bbs2-0120" title="Joint Formulary Committee. British National Formulary No 82. Pharmaceutical Press, 2021. [ISBN: 9780857114136]">BNF 2021</a>). Although all trials of appetite stimulants reported some adverse events, data were difficult to interpret because trials were underpowered to detect clinically important differences. Furthermore, the reporting of adverse events was not consistent, and there were no reports on the frequency in adverse events per patient years. Despite these important limitations, the results suggest a potential positive effect of appetite stimulants on both weight gain and appetite. In order to judge which appetite stimulant to use with individuals and to make an informed decision, clinicians require information on: significant gains in appetite and weight; type; age of use; starting and maximum dosages; and the effect of ceasing stimulants.  </p> <p>Hence, at present, the dose of appetite stimulants and duration of therapy should fall within the short‐term range (e.g. six months) as used in the trials reviewed. Clinicians need to be aware of the potential adverse effects of these medications and actively monitor patients accordingly. The clinical benefits of appetite stimulants in CF need to be balanced against the risks of potential adverse events and considered on a case‐by‐case basis. </p> </section> <h3 class="title" id="CD008190-sec-0102">Implications for research</h3> <section id="CD008190-sec-0102"> <p>In order to further our understanding of the role of appetite stimulants in CF, it is first necessary to determine meaningful surrogate measures for appetite, as well as define what constitutes quality weight gain. This will then allow much more precise and meaningful research to be conducted into appetite stimulants. Trials should evaluate the effectiveness of MA and CH on poor appetite in CF. Further research must define the best direct method of documenting the presence of poor appetite. Trials should use a validated measure of symptoms, and should include a disease‐specific instrument for measuring poor appetite. There are currently no validated scoring systems for grading appetite, and the best objective measure of evaluating appetite has yet to be defined. </p> <p>Given that based on RCTs, there is insufficient evidence for any more than short‐term use of appetite stimulants in CF, this review highlights the need for multicentred, adequately powered, and well‐designed trials to prove or disprove the potential of these agents to increase appetite safely in CF, and to establish the optimal mode of treatment. </p> <p>Research is further complicated by the fact that the aetiology of poor appetite may be multifactorial and is not fully understood. There are also uncertainties not only about the effective duration and appropriate dose, but also the side effects of appetite stimulants in both adults and children with CF. </p> <p>Gaps in the current knowledge and issues for future trials are as follows.</p> <p> <ul id="CD008190-list-0012"> <li> <p>Do appetite stimulants actually improve appetite, and what is the magnitude of this effect? </p> </li> <li> <p>Do appetite stimulants result in sustained weight gain?</p> </li> <li> <p>What quality of weight gain is considered clinically significant?</p> </li> <li> <p>What quality of weight gain can be expected from appetite stimulants?</p> </li> <li> <p>Which side effects should be monitored, and what is their clinical significance?</p> </li> <li> <p>When should appetite stimulant administration begin and end, alongside the duration and clinical indications? </p> </li> <li> <p>Which appetite stimulants work best for toddlers, children, prepubertal children, teenagers, young adults, and adults? </p> </li> <li> <p>Should treatment vary according to whether the individual is awaiting transplantation?</p> </li> <li> <p>Should some steroid‐based appetite stimulants be contraindicated for listed lung‐transplant patients because of potential bone loss whilst on steroids (<a href="./references#CD008190-bbs2-0157" title="TschoppO , BoehlerA , SpeichR , WederW , SeifertB , RussiEW , et al. Osteoporosis before lung transplantation: association with low body mass index, but not with underlying disease. American Journal of Transplantation2002;2(2):167-72.">Tschopp 2002</a>)? </p> </li> <li> <p>Which are the important patient‐related outcomes when taking appetite stimulants?</p> </li> </ul> </p> <p>These questions remain unanswered because currently available trials lack important clinical outcomes and are underpowered to detect differences in treatment effects across subgroups of participants, resulting in overall poor‐quality data. The conduct of future RCTs needs to be improved with unbiased and clear reporting of clinically significant outcomes in accordance with the CONSORT statement (<a href="./references#CD008190-bbs2-0139" title="IoannidisJP , EvansSJ , GøtzschePC , O’NeillRT , AltmanDG , SchulzK , et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine2004;141(10):781-8.">Ioannidis 2004</a>; <a href="./references#CD008190-bbs2-0143" title="MoherD , SchulzKF , AltmanDG . The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet2001;357(9263):1191-4.">Moher 2001</a>; <a href="./references#CD008190-bbs2-0144" title="MoherD , SchulzKF , AltmanDG . The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Clinical Oral Investigations2003;7(1):2-7.">Moher 2003</a>; <a href="./references#CD008190-bbs2-0145" title="MoherD , AltmanDG , SchulzKF , ElbourneDR . Opportunities and challenges for improving the quality of reporting clinical research: CONSORT and beyond. Canadian Medical Association Journal2004;171(4):349-50.">Moher 2004</a>). </p> <p>We recommend that future RCTs:</p> <p> <ul id="CD008190-list-0013"> <li> <p>are adequately powered and robust, designed to elucidate the magnitude in effect for both clinical and patient‐related relevant outcomes, i.e. appetite change, lung function, cost per quality‐adjusted life year (QALY), quality of life (e.g. sick leave from employment, functional ability, and psychological impact); </p> </li> <li> <p>define clinically significant weight gain in both children and adults;</p> </li> <li> <p>establish valid surrogate markers of appetite change (both objective and subjective);</p> </li> <li> <p>report changes in nutritional and dietary intake along with changes in predefined surrogate markers for appetite change; </p> </li> <li> <p>report on a predefined list of adverse effects, as well as monitoring any unexpected adverse effects for all age groups; </p> </li> <li> <p>ensure complete data sets are reported for all outcomes (including mean change data and their standard deviations); and </p> </li> <li> <p>report outcome differences and standard deviations of differences to allow for meaningful meta‐analyses. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008190-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008190-sec-0008"></div> <div class="table" id="CD008190-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Appetite stimulants versus placebo for people with cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Appetite stimulants versus placebo for people with cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with cystic fibrosis </p> <p><b>Setting:</b> outpatients </p> <p><b>Intervention:</b> appetite stimulants </p> <p><b>Comparison</b>: placebo<br/>  </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Appetite stimulants</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in weight (kg)</b> </p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in weight ranged from 0.67 kg to 1.3 kg.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in weight (kg) in the intervention group was <b>1.25 kg</b> <b>higher</b> (0.45 higher to 2.05 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>a,b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in weight (kg)</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in weight was 1.5 kg.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in weight (kg) in the intervention group was <b>3.8 kg higher</b> (1.27 to 6.33 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>a,b</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in weight z score</b> </p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in weight z score ranged from −0.05 to 0.07.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in weight z score in the intervention group was <b>0.61 higher</b> (0.29 higher to 0.93 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>b,c</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in weight z score</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in weight z score was 0.02.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in weight z score in the intervention group was <b>0.74 higher</b> (0.26 to 1.22 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>a,b</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in FEV<sub>1</sub> % predicted</b> </p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted ranged from −3.7% to −1.81%. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted in the intervention group was <b>4.26% higher</b> (5.45 lower to 13.97 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>a,b</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in FEV<sub>1</sub> % predicted</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted was 0.83. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted in the intervention group was <b>5.64 higher</b> (4.43 lower to 15.71 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>a,b</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Increase in appetite (subjective reporting)</b> </p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Of the 23 participants responding to the questionnaires, all 10 participants who took appetite stimulants reported a subjective increase in appetite, compared to only 2 out of 13 participants in the placebo group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 45.25</p> <p>(3.57 to 573.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>d,e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The numbers  were too small to calculate the corresponding risk, therefore results have been reported narratively. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume at one second; <b>OR:</b> odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b>: we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty</b>: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty</b>: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once due to risk of attrition and reporting bias.<br/><sup>b</sup>Downgraded once for imprecision due to small number of participants.<br/><sup>c</sup>Downgraded once due to risk of attrition and reporting bias as well as unclear risk of selection bias.<br/><sup>d</sup>Downgraded once due to risk of bias within the included trials as follows: one study was at unclear risk of bias for the randomisation process, and both studies were at unclear risk for allocation concealment; one study was at high risk of attrition bias; and both studies were at high risk of reporting bias.<br/><sup>e</sup>Downgraded once for imprecision due to very low participant numbers and low event rates. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008190-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008190-sec-0009"></div> <p>For an explanation of terms used in this review, please see the glossary (<a href="./appendices#CD008190-sec-0108">Appendix 1</a>). </p> <section id="CD008190-sec-0010"> <h3 class="title" id="CD008190-sec-0010">Description of the condition</h3> <p>Treating and managing loss of weight, inadequate weight gain, and failure to thrive can be challenging in cystic fibrosis (CF). Weight loss is a complex problem contributed to, in part, by anorexia (leading to reduced energy intake resulting in reduced nutrient absorption) and also by intestinal malabsorption. An increased resting energy expenditure, as a result of deteriorating pulmonary function and chronic sepsis, also contributes to weight loss (<a href="./references#CD008190-bbs2-0126" title="ElbornJS , BellSC . Nutrition and survival in cystic fibrosis. Thorax1996;51(10):971–2.">Elborn 1996</a>). This results in a recurring cycle of weight loss and malnutrition, contributing to reduced lung function, a lower quality of life (QoL), and increased morbidity and mortality (<a href="./references#CD008190-bbs2-0135" title="HardinDS . Growth problems and growth hormone treatment in children with cystic fibrosis. Journal of Pediatric Endocrinology &amp; Metabolism2002;15(Suppl 2):731-5.">Hardin 2002</a>; <a href="./references#CD008190-bbs2-0150" title="SharmaR , FloreaVG , BolgerAP , DoehnerW , FloreaND , CoatsAJ , et al. Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax2001;56(10):746-50.">Sharma 2001</a>; <a href="./references#CD008190-bbs2-0152" title="SinaasappelM , SternM , LittlewoodJ , WolfeS , SteinkampG , HeijermanHG , et al. Nutrition in patients with cystic fibrosis: a European Consensus. Journal of Cystic Fibrosis2002;1(2):51-75.">Sinaasappel 2002</a>). Furthermore, pulmonary exacerbations have important adverse effects on body protein metabolism (<a href="./references#CD008190-bbs2-0151" title="ShepherdRW , HoltTL , CleghornG , WardLC , IslesA , FrancisP . Short-term nutritional supplementation during management of pulmonary exacerbations in cystic fibrosis: a controlled study, including effects of protein turnover. American Journal of Clinical Nutrition1998;48(2):235-9.">Shepherd 1998</a>). Symptoms of anorexia, weight loss, and tissue wasting, combined with a decrease in muscle mass and adipose tissue, are together known as anorexia‐cachexia syndrome (<a href="./references#CD008190-bbs2-0060" title="LópezAP , FigulsRM , CuchiGU , BerensteinEG , PasiesBA , AlegreMB , et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. Journal of Pain and Symptom Management2004;27(4):360-9. ">Lopez 2004</a>). Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have shown some improvements in anthropometry dependent on genetic mutation and the modulator used (<a href="./references#CD008190-bbs2-0116" title="BaileyJ , RozgaM , McDonaldCM , BowserEK , FarnhamK , MangusM , et al. Effect of CFTR modulators on anthropometric parameters in individuals with cystic fibrosis: an evidence analysis center systematic review. Journal of the Academy of Nutrition and Dietetics2021;121(7):1364-78.">Bailey 2021</a>). The importance of maintaining optimal nutrition in people with CF is well‐recognised. However, the exact mechanism of anorexia in CF remains uncertain (<a href="./references#CD008190-bbs2-0013" title="BerensteinG , OrtizZ . Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD004310. [DOI: 10.1002/14651858.CD004310.pub2]">Berenstein 2005</a>), and there is as yet no objective method of assessing appetite in CF. Inadequate appetite tends to be diagnosed through elimination of all other contributory factors (<a href="./references#CD008190-bbs2-0069" title="NasrSZ , DruryD . Appetite stimulants use in cystic fibrosis. Pediatric Pulmonology2008;43(3):209-19. ">Nasr 2008</a>). The aetiology of anorexia is likely to be multifactorial: it may be caused in part by chronic infection due to factors such as increased mucus production and the anorectic effects of elevated serum inflammatory cytokines (<a href="./references#CD008190-bbs2-0126" title="ElbornJS , BellSC . Nutrition and survival in cystic fibrosis. Thorax1996;51(10):971–2.">Elborn 1996</a>). Tumour necrosis factor (TNF)‐α in particular may be implicated (<a href="./references#CD008190-bbs2-0155" title="SuterS , SchaadUB , Roux-LombardP , GirardinE , GrauG , DayerJM . Relation between tumor necrosis factor-alpha and granulocyte elastase-alpha 1-proteinase inhibitor complexes in the plasma of patients with cystic fibrosis. American Review of Respiratory Disease1989;140(6):1640-4.">Suter 1989</a>). In addition, anorexia may be related to the presence of severe sinusitis, gastro‐oesophageal reflux, and protein or energy malnutrition (or both) (<a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>). </p> <p>Currently, little is known about the incidence and aetiology of anorexia and poor appetite in CF, and there is no consensus on the management of these symptoms to date (<a href="./references#CD008190-bbs2-0018" title="ChinuckRS , FortnumH , BaldwinDR . Appetite stimulants in cystic fibrosis: a systematic review. Journal of Human Nutrition and Dietetics2007;20(6):526-37. ">Chinuck 2007</a>; <a href="./references#CD008190-bbs2-0146" title="O'BrienCE , HardenH , ComG . A survey of nutrition practices for patients with cystic fibrosis. Nutrition in Clinical Practice2013;28(2):237-41.">O'Brien 2013</a>). </p> </section> <section id="CD008190-sec-0011"> <h3 class="title" id="CD008190-sec-0011">Description of the intervention</h3> <p>Whilst appetite stimulants are prescribed to people with CF, they are not currently licensed for use in CF in either adults or children. They are used as part of an array of treatment for anorexia and weight loss, but their use is controversial because of doubts about efficacy and concerns about toxicity. Research to date has consisted of small, sometimes poorly conducted studies. Multiple agents have been studied in the CF population which may have a secondary effect on appetite stimulation. These agents have a range of primary characteristics and include hormones (ghrelin, growth hormone, insulin), antihistamines (cyproheptadine (CH), pizotifen), steroids (megestrol acetate (MA), oxandrolone, prednisone), cannabinoids (dronabinol), antidepressants (mirtazapine), and antipsychotics (olanzapine). In addition to agents that have already been studied in CF, there are other interventions with possible similar effects that could have implications for people with CF. Given this wide range of agents, a definition of an appetite stimulant for consideration in this review will be: an agent with a biologically plausible mechanism by which it may stimulate appetite and where it is prescribed specifically for that indication. We will thus restrict the interventions considered to be appetite stimulants for the purpose of this review to: CH, MA, oxandrolone, dronabinol, mirtazapine, pizotifen, risperidone, and olanzapine. All agents are administered orally. </p> <section id="CD008190-sec-0012"> <h4 class="title">Cyproheptadine</h4> <p>CH is used as an antihistamine, and clinical recommended dosages differ in children and adults (<a href="./references#CD008190-bbs2-0119" title="British National Formulary. Periactin. www.medicinescomplete.com/mc/bnf/current/PHP1940-periactin.htm#PHP1940-periactin (accessed 5 June 2014).">BNF 2014</a>). It has been investigated for use as an appetite stimulant in CF (<a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>; <a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>). </p> </section> <section id="CD008190-sec-0013"> <h4 class="title">Dronabinol</h4> <p>Capsules of synthetic tetrahydrocannabinol (THC) (dronabinol) have been available for restricted medical use in the USA since 1985. Nabilone, a synthetic THC analogue taken orally, is the only cannabinoid licensed for prescription in the UK for the treatment of nausea and vomiting caused by chemotherapy; its use in other indications is only possible on a ‘named patient’ basis if the drug is supplied by a hospital pharmacy (<a href="./references#CD008190-bbs2-0128" title="Electronic Medicines Compendium. Nabilone tablets 1 mg. www.medicines.org.uk/emc/medicine/20515/SPC/Nabilone+1mg+Capsules (accessed 25 March 2014).">EMC 2014a</a>). Dronabinol has been shown to be effective as an oral appetite stimulant in people with HIV or cancer at doses of 2.5 mg to a maximum of 5 mg twice daily (<a href="./references#CD008190-bbs2-0008" title="AnsteadMI , KuhnRJ , MartynD , CraigmyleL , KangaJF . Dronabinol, an effective and safe appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. ">Anstead 2003</a>). </p> </section> <section id="CD008190-sec-0014"> <h4 class="title">Megestrol acetate</h4> <p>The progestogen steroid MA (Megace) is mainly used as a treatment for breast cancer in women; in addition, MA is sometimes used to treat cancer of the uterus and prostate cancer (<a href="./references#CD008190-bbs2-0129" title="Electronic Medicines Compendium. Megace 160 mg tablets. www.medicines.org.uk/emc/medicine/346/SPC/Megace+160+mg+Tablets (accessed 26 March 2014).">EMC 2014b</a>). One of its adjunctive effects is weight gain, and it has been used for appetite stimulation and weight gain for such indications as advanced cancer, AIDS, and the elderly (<a href="./references#CD008190-bbs2-0060" title="LópezAP , FigulsRM , CuchiGU , BerensteinEG , PasiesBA , AlegreMB , et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. Journal of Pain and Symptom Management2004;27(4):360-9. ">Lopez 2004</a>); renal failure (<a href="./references#CD008190-bbs2-0019" title="ChungSH , StenvinkelP , LindholmB , AvesaniCM . Identifying and managing malnutrition stemming from different causes. Peritoneal Dialysis International2006;27(Suppl 2):S239-44. ">Chung 2006</a>; <a href="./references#CD008190-bbs2-0138" title="HobbsDJ , BunchmanTE , WeismantelDP , ColeMR , FergusonKB , GastTR , et al. Megestrol acetate improves weight gain in pediatric patients with chronic kidney disease. Journal of Renal Nutrition2012;20(6):408-13.">Hobbs 2012</a>); chronic heart failure (<a href="./references#CD008190-bbs2-0159" title="vonHaehlingS , LainscakM , SpringerJ , AnkerSD . Cardiac cachexia: a systematic overview. Pharmacology &amp; Therapeutics2009;121(3):227-52. [DOI: 10.1016/j.pharmthera.2008.09.009]">von Haehling 2009</a>); chronic obstructive pulmonary disease (<a href="./references#CD008190-bbs2-0112" title="WeisbergJ , WangerJ , JefferyO , StritB , FogartyC , MartinT , et al. Megesterol acetate stimulates weight gain and ventilation in underweight COPD patients. Chest2002;121(4):1070-8. ">Weisberg 2002</a>); and CF (<a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>; <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>). </p> <p>MA is not very water‐soluble, thus its bio‐availability is low, although bio‐availability is improved if it is taken with food. Several formulations have been developed in an attempt to improve bio‐availability (e.g. a micronised tablet form and a concentrated oral suspension). The most recent of these is an oral suspension form using nanocrystal technology, which is licensed for anorexia‐cachexia in people with AIDS. </p> </section> <section id="CD008190-sec-0015"> <h4 class="title">Mirtazapine</h4> <p>Mirtazapine (Remeron) is typically used as an antidepressant in tablet form, and the dosage differs between initial and maintenance treatment (<a href="./references#CD008190-bbs2-0130" title="Electronic Medicines Compendium. Mirtazapine 15 mg tablets. www.medicines.org.uk/emc/medicine/24969/SPC/Mirtazapine+15+mg+orodispersible+tablets (accessed 25 March 2014).">EMC 2014c</a>). In two trials evaluating its role as an appetite stimulant in people with CF, mirtazapine was given at a doses ranging from 15 mg to 45 mg per day (<a href="./references#CD008190-bbs2-0101" title="SykesR , KittellF , MarcusM , TarterE , SchrothM . Mirtazapine for appetite stimulation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 Suppl 29:389. ">Sykes 2006</a>; <a href="./references#CD008190-bbs2-0113" title="YoungJ , DanduranMJ , McColleySA , BoarSR . The role of mirtazapine as an appetite stimulant in malnourished individuals with CF [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. ">Young 2000</a>). </p> </section> <section id="CD008190-sec-0016"> <h4 class="title">Olanzipine</h4> <p>Olanzipine is an atypical antipsychotic drug (<a href="./references#CD008190-bbs2-0131" title="Electronic Medicines Compendium. Olanzapine Sandoz 20 mg film-coated tablets. www.medicines.org.uk/emc/medicine/25455/SPC/Olanzapine+Sandoz+20+mg+Film-coated+Tablets (accessed 26 March 2014).">EMC 2014d</a>). Whilst limited data are available, olanzapine has been used to stimulate appetite and improve body mass index (BMI) and other disease‐related symptoms (e.g. eating attitudes, anxiety) in people with anorexia aged nine years and older. The dose used to stimulate appetite has been higher than that used in psychiatric practice (<a href="./references#CD008190-bbs2-0069" title="NasrSZ , DruryD . Appetite stimulants use in cystic fibrosis. Pediatric Pulmonology2008;43(3):209-19. ">Nasr 2008</a>). </p> </section> <section id="CD008190-sec-0017"> <h4 class="title">Oxandrolone</h4> <p>Therapy with the anabolic steroid oxandrolone (Oxandrin) should be intermittent, and the duration should depend on an individual's response and adverse reactions. Two‐ to four‐week blocks of therapy are usually adequate, and dosage differs depending on the age of the individual (<a href="./references#CD008190-bbs2-0142" title="MedLibrary (Food &amp; Drug Agency). Oxandrolone. www.medlibrary.org/lib/info/google-search/?cx=partner-pub-3862246084592963%3A1mitg9hzsad&amp;cof=FORID%3A10&amp;ie=UTF-8&amp;q=oxandrolone&amp;sa=Search&amp;siteurl=medlibrary.org%2F&amp;ref=&amp;ss=4143j3496931j13 (accessed 18 June 2014).">MedLibrary 2014</a>; <a href="./references#CD008190-bbs2-0158" title="Upsher-Smith Laboratories, Inc. Oxandrolone tablets. www.upsher-smith.com/products/oxandrolone-tablets-usp-ciii/ (accessed 30 August 2022).">Upsher‐Smith 2022</a>). Oxandrolone has been used principally in anorexia in people with cancer, but it has also been investigated in CF (<a href="./references#CD008190-bbs2-0105" title="TongudaiS , BravermanS , KirkpatrickJA , HuangNN . Evaluation of oxandrolone in patients with cystic fibrosis. In: 12th Annual Meeting Cystic Fibrosis Club Abstracts; 1971 Apr 28; Atlantic City (NJ). 1971:54. ">Tongudai 1971</a>; <a href="./references#CD008190-bbs2-0108" title="VarnessT , SeffroodEE , ConnorEL , RockMJ , AllenDB . Oxandrolone improves height velocity and BMI in patients with cystic fibrosis. International Journal of Pediatric Endocrinology 2010 Jan 24 [Epub ahead of print]. [DOI: 10.1155/2009/826895]">Varness 2009</a>). </p> </section> <section id="CD008190-sec-0018"> <h4 class="title">Pizotifen</h4> <p>Pizotifen is an antihistamine and serotonin antagonist used to treat migraine at differing age‐dependent doses (<a href="./references#CD008190-bbs2-0132" title="Electronic Medicines Compendium. Pizotifen tablets 0.5 mg. www.medicines.org.uk/emc/medicine/24179/SPC/Pizotifen+Tablets+0.5mg/ (accessed 25 March 2014).">EMC 2014e</a>). </p> </section> <section id="CD008190-sec-0019"> <h4 class="title">Risperidone</h4> <p>Risperidone is indicated in the treatment of acute and chronic psychoses, and in the management of aggression in moderate to severe Alzheimer’s dementia. Recommended doses vary depending on the condition being treated and the age and weight of the individual (<a href="./references#CD008190-bbs2-0133" title="Electronic Medicines Compendium. Risperdal Tablets, Liquid &amp; Quicklet. www.medicines.org.uk/emc/medicine/12818/SPC (accessed 26 March 2014).">EMC 2014f</a>). It is not recommended for use in children, except for conduct disorder and then only for children over five years of age. </p> </section> </section> <section id="CD008190-sec-0020"> <h3 class="title" id="CD008190-sec-0020">How the intervention might work</h3> <p>Given that the agents vary in type, the mechanisms of action are varied and mostly unclear in people with CF. </p> <section id="CD008190-sec-0021"> <h4 class="title">Cyproheptadine</h4> <p>CH is a serotonin and histamine antagonist approved by the US Food and Drug Administration (FDA) for use in children for allergic rhinitis, allergic conjunctivitis, urticaria, dermatographism, and mild angio‐oedema. Unexplained weight gain has been observed in people with CF who have taken CH. </p> </section> <section id="CD008190-sec-0022"> <h4 class="title">Dronabinol</h4> <p>Dronabinol is the principal psychoactive substance present in marijuana (<a href="./references#CD008190-bbs2-0069" title="NasrSZ , DruryD . Appetite stimulants use in cystic fibrosis. Pediatric Pulmonology2008;43(3):209-19. ">Nasr 2008</a>). However, the mechanism of action in CF is unreported (<a href="./references#CD008190-bbs2-0008" title="AnsteadMI , KuhnRJ , MartynD , CraigmyleL , KangaJF . Dronabinol, an effective and safe appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. ">Anstead 2003</a>). </p> </section> <section id="CD008190-sec-0023"> <h4 class="title">Megestrol acetate</h4> <p>It has been elucidated that MA may cause appetite stimulation and weight gain in people with anorexia or cachexia, or both (<a href="./references#CD008190-bbs2-0061" title="LoprinziCL , SchaidDJ , DoseAM , BurnhamNL , JensenMD . Body-composition changes in patients who gain weight while receiving megestrol acetate. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology1993;11(1):152-4. ">Loprinzi 1993</a>). The mechanism by which this occurs has not been established, but it has been shown to have the secondary effect of appetite stimulation (<a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>). Increased levels of cytokines are known to be associated with anorexia and cachexia in people with cancer (<a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>). It has been reported that MA inhibits cytokines and so may be a treatment option for cachexia (<a href="./references#CD008190-bbs2-0156" title="TayorC . The regulation of appetite in cystic fibrosis symposium. In: 30th Congress European Cystic Fibrosis Society; 2007 Jun 13‐16; Belek, Turkey. 2007.">Taylor 2007</a>). Additionally, it has been hypothesised that cytokines inhibit the action of TNF on fatty tissue and its products (<a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>), and that cytokines released during inflammation and malignancy act on the central nervous system to alter the release and function of a number of neurotransmitters, thereby altering both appetite and metabolic rate (<a href="./references#CD008190-bbs2-0134" title="GrossbergAJ , ScarlettJM , MarksDL . Hypothalamic mechanisms in cachexia. Physiology and Behavior2010;100(5):478-89.">Grossberg 2010</a>). However, this has not been elucidated in CF. </p> </section> <section id="CD008190-sec-0024"> <h4 class="title">Mirtazapine</h4> <p>Mirtazapine has noradrenergic‐ and serotonergic‐enhancing properties as well antihistamine effects, and a common side effect observed is appetite stimulation (<a href="./references#CD008190-bbs2-0113" title="YoungJ , DanduranMJ , McColleySA , BoarSR . The role of mirtazapine as an appetite stimulant in malnourished individuals with CF [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. ">Young 2000</a>). </p> </section> <section id="CD008190-sec-0025"> <h4 class="title">Olanzipine</h4> <p>Olanzipine, an antipsychotic, is associated with clearly documented weight gain and adverse metabolic effects. Although increased appetite or caloric intake and various receptors, hormones, and peptides have been implicated, the biological mechanisms contributing to the increase in weight and glucose and lipid abnormalities with antipsychotics are largely unknown (<a href="http://archie.cochrane.org/sections/documents/view?version=z1405191713002082467044980876943&amp;format=REVMAN#STD-Nasr-2008" target="_blank">Nasr 2008</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1405191713002082467044980876943&amp;format=REVMAN#STD-Nasrallah-2003" target="_blank">Nasrallah 2003</a>). </p> </section> <section id="CD008190-sec-0026"> <h4 class="title">Oxandralone</h4> <p>Oxandralone is weak oral androgen which has anabolic properties with minimal androgenic effects (<a href="./references#CD008190-bbs2-0108" title="VarnessT , SeffroodEE , ConnorEL , RockMJ , AllenDB . Oxandrolone improves height velocity and BMI in patients with cystic fibrosis. International Journal of Pediatric Endocrinology 2010 Jan 24 [Epub ahead of print]. [DOI: 10.1155/2009/826895]">Varness 2009</a>). </p> </section> <section id="CD008190-sec-0027"> <h4 class="title">Pizotifen</h4> <p>Pizotifen is a sedating antihistamine which is reported to have an orexigenic effect in people with pulmonary tuberculosis (<a href="./references#CD008190-bbs2-0081" title="OhnhausEE , NueschE . Lack of effect of the appetite stimulant pizotifen on the absorption of isonicotinylhydrazine. European Journal of Clinical Pharmacology1974;7(1):59-60. ">Ohnhaus 1974</a>). However, as with CH, its mechanism of action as an appetite enhancer is unclear. </p> </section> <section id="CD008190-sec-0028"> <h4 class="title">Risperidone</h4> <p>Risperidone may cause weight gain due to the blockade of certain receptors, for example 5‐HT2c, that modulate appetite and body weight, and is associated with modest weight changes that are not dose‐related. However, the mechanisms involved in drug‐related weight gain for both risperidone and olanzapine are as yet uncertain (<a href="./references#CD008190-bbs2-0069" title="NasrSZ , DruryD . Appetite stimulants use in cystic fibrosis. Pediatric Pulmonology2008;43(3):209-19. ">Nasr 2008</a>; <a href="./references#CD008190-bbs2-0070" title="NasrallahH . A review of the effect of atypical antipsychotics on weight. Psychoneuroendrocrinology2003;28:83-96. ">Nasrallah 2003</a>). </p> </section> </section> <section id="CD008190-sec-0029"> <h3 class="title" id="CD008190-sec-0029">Why it is important to do this review</h3> <p>Nutrition and weight are cornerstones of CF management. A lack of appetite has not only been reported as a common indicator of pulmonary exacerbation in people with CF (<a href="./references#CD008190-bbs2-0115" title="AbbottJ , HoltA , MortonAM , HartA , MilneG , WolfeSP , et al. Patient indicators of a pulmonary exacerbation: preliminary reports from school aged children map onto those of adults. Journal of Cystic Fibrosis2012;11(3):180-6.">Abbott 2011</a>), but also plays a key role in weight loss. The use of appetite stimulants in CF is controversial because of doubts concerning efficacy and also due to possible side effects. Hence the aim of this review was to establish whether appetite stimulants should be recommended in people with CF. This is an updated version of the original review (<a href="./references#CD008190-bbs2-0161" title="ChinuckR , DewarJ , BaldwinDR , HendronE . Appetite stimulants for people with cystic fibrosis. Cochrane Database of Systematic Reviews2014, Issue 7. Art. No: CD008190. [DOI: 10.1002/14651858.CD008190.pub2]">Chinuck 2014</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008190-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008190-sec-0030"></div> <p>To systematically search for and evaluate the evidence on the beneficial effects of appetite stimulants in the management of CF‐related anorexia and synthesise reports of any side effects. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008190-sec-0031" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008190-sec-0031"></div> <section id="CD008190-sec-0032"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008190-sec-0033"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) and quasi‐RCTs (with no language restrictions).</p> </section> <section id="CD008190-sec-0034"> <h4 class="title">Types of participants</h4> <p>People with CF (diagnosed clinically and confirmed with sweat test or genetic testing or both) of any age, irrespective of pancreatic insufficiency or sufficiency and of any disease severity. </p> </section> <section id="CD008190-sec-0035"> <h4 class="title">Types of interventions</h4> <p>We considered an appetite stimulant to be an agent with a biologically plausible mechanism by which it may stimulate appetite and where it is prescribed specifically for that indication (addition of this definition is a post hoc change). In light of this definition, we considered trials eligible for inclusion if they compared appetite stimulants or any agent used as an appetite stimulant to placebo, control, or no treatment; different appetite stimulants; or the same appetite stimulants at different doses or regimens of at least one month duration. </p> </section> <section id="CD008190-sec-0036"> <h4 class="title">Types of outcome measures</h4> <p>We have reported on the following outcomes.</p> <section id="CD008190-sec-0037"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD008190-list-0001"> <li> <p>Change in body weight (kg)</p> </li> <li> <p>Change in body composition</p> <ol id="CD008190-list-0002"> <li> <p>lean body mass (LBM)</p> </li> <li> <p>fat mass</p> </li> <li> <p>body mass index (BMI)</p> </li> </ol> </li> <li> <p>Change in pulmonary function</p> <ol id="CD008190-list-0003"> <li> <p>forced expiratory volume in one second (FEV<sub>1</sub>) (L) </p> </li> <li> <p>FEV<sub>1</sub> % predicted </p> </li> </ol> </li> </ol> </p> </section> <section id="CD008190-sec-0038"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD008190-list-0004"> <li> <p>Subjective report of anorexia or change in appetite, or both</p> </li> <li> <p>Quality of life (QoL) (subjective report or measured by a validated questionnaire)</p> </li> <li> <p>Dietary intake:</p> <ol id="CD008190-list-0005"> <li> <p>energy intake (measured in kilocalories (kcal) per day);</p> </li> <li> <p>protein intake (measured in grams of protein per day).</p> </li> </ol> </li> <li> <p>Any adverse events directly related to the intervention</p> </li> <li> <p>Change in the number of pulmonary exacerbations</p> </li> </ol> </p> </section> </section> </section> <section id="CD008190-sec-0039"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all relevant published and unpublished trials without any language restrictions (we did not exclude trials reported in a language other than English), year, or publication status. </p> <section id="CD008190-sec-0040"> <h4 class="title">Electronic searches</h4> <p>We identified relevant trials from the Cochrane Cystic Fibrosis and Genetic Disorders Group's Cystic Fibrosis Trials Register using the terms: appetite stimulant OR treatment of growth failure OR depression OR psychosis OR insulin OR anabolic steroid OR headache.  </p> <p>The Cystic Fibrosis Trials Register was compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the Cochrane Library), quarterly searches of MEDLINE, a search of Embase to 1980, and the prospective handsearching of two journals: <i>Pediatric Pulmonology</i> and <i>Journal of Cystic Fibrosis</i>. We identified unpublished work by searching the abstract books of three major cystic fibrosis conferences: the International Cystic Fibrosis Conference; the European Cystic Fibrosis Conference; and the North American Cystic Fibrosis Conference. For full details of all searching activities for the register, please see the relevant sections of the Cystic Fibrosis and Genetic Disorders Group's <a href="https://cfgd.cochrane.org/" target="_blank">website</a>. </p> <p>Date of the last search of the Cystic Fibrosis Trials Register: 23 May 2022.</p> <p>We also searched the following databases and trial registries:</p> <p> <ol id="CD008190-list-0006"> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="https://clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>; searched 10 May 2022); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="https://trialsearch.who.int/" target="_blank">apps.who.int/trialsearch</a>; searched 10 May 2022). </p> </li> </ol> </p> <p>The previous author team also searched these additional resources for a previous version of this review, but this has not been updated as the current author team do not have access to this resource: </p> <p> <ol id="CD008190-list-0007"> <li> <p>MEDLINE HDAS (1946 to 1 April 2014);</p> </li> <li> <p>Embase HDAS (1974 to 1 April 2014);</p> </li> <li> <p>CINAHL HDAS (Cumulative Index to Nursing and Allied Health Literature; 1982 to 1 May 2012). </p> </li> </ol> </p> <p>Details of the search strategies can be found in <a href="./appendices#CD008190-sec-0109">Appendix 2</a>.   </p> </section> <section id="CD008190-sec-0041"> <h4 class="title">Searching other resources</h4> <p>We checked the bibliographies of included trials and any relevant systematic reviews identified for further references to relevant trials. We also contacted the authors of conference abstracts to determine if further publications were in press. </p> <p>We also requested additional material such as unpublished further trials and negative trials from personal contacts with experts and the suppliers of appetite stimulants (Bristol‐Myers Squibb and Actavis Mid Atlantic LLC). </p> </section> </section> <section id="CD008190-sec-0042"> <h3 class="title" id="CD008190-sec-0042">Data collection and analysis</h3> <section id="CD008190-sec-0043"> <h4 class="title">Selection of studies</h4> <p>Two review authors (RC and JD for the original review and DM and JT for the subsequent updates) independently screened the titles and abstracts of trials identified by the searches and selected those that potentially met the selection criteria. We obtained the full‐text articles of potentially relevant trials and the review authors assessed these for inclusion in the review. The review authors extracted and entered details onto the generic trial selection and data extraction form developed by the Cochrane Cystic Fibrosis and Genetic Disorders Review Group. This process encouraged adherence to our inclusion criteria in order to avoid including trials that were not exclusively researching agents prescribed for appetite or that may not work on appetite stimulation. </p> <p>In the event of uncertainty or disagreement on trial selection, this was resolved through discussion or by consultation with a member of the editorial base.  </p> </section> <section id="CD008190-sec-0044"> <h4 class="title">Data extraction and management</h4> <p>Review authors independently extracted data from the included trials, cross‐checked data reported for the outcomes listed in <a href="#CD008190-sec-0036">Types of outcome measures</a>, discussed any differences, and reached a consensus on the extracted data. If review authors were unable to extract data, they reported the outcome results narratively. </p> <p>We planned to assess outcome measures at the time points of over one and up to six months and at six‐monthly intervals thereafter. In the current version of the review, we presented data from the included trials at three and six months, leading to a difference between the protocol and the review. However, it was not considered clinically relevant to combine the time points at three and six months. </p> </section> <section id="CD008190-sec-0045"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Review authors independently assessed the risk of bias for each included trial (without blinding to authorship or journal publication) following the domain‐based assessment tool described in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008190-bbs2-0137" title="HigginsJP , AltmanDG , Sterne JA on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). This comprised a description and a judgement for each entry in a risk of bias table, where each entry addresses a specific feature of the trial. The judgement for each entry involved answering a question, with an answer of low risk of bias, high risk of bias, or unclear risk of bias (indicating either lack of information or uncertainty over the potential for bias). The review authors assessed the following risk of bias domains: randomisation procedure; allocation concealment; blinding of investigators, participants, and outcome assessors; intention‐to‐treat analysis, completeness of follow‐up, and incomplete outcome data; selective reporting; and other potential sources of bias. We also noted details of statistical assessment such as differences in means, overall treatment effects, heterogeneity, and subgroup and sensitivity analyses. We presented this information in risk of bias tables (see <a href="./references#CD008190-sec-0123" title="">Characteristics of included studies</a>). Any discrepancies were resolved by consensus or by discussion with a member of the editorial base when necessary. Further details regarding the risk of bias tool are provided in <a href="#CD008190-tbl-0002">Table 1</a>. </p> <div class="table" id="CD008190-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Cochrane risk of bias tool</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Domain</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Description</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Review authors’ judgement</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation</b> </p> <p><b>(selection bias)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Description of the method used to generate the allocation sequence in sufficient detail to permit an assessment of whether it should produce comparable groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Was the allocation sequence adequately generated?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Allocation concealment</b> </p> <p><b>(selection bias)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Description of the method used to conceal the allocation sequence in sufficient detail to determine whether intervention allocations could have been foreseen in advance of, or during, enrolment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Was allocation adequately concealed?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Blinding of participants, personnel, and outcome assessors</b> </p> <p><b>(performance bias and detection bias)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Description of measures used, if any, to blind study participants, personnel, and outcome assessors from knowledge of which intervention a participant received. Any information relating to whether the intended blinding was effective </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Was knowledge of the allocated intervention adequately prevented during the study?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incomplete outcome data</b> </p> <p><b>(attrition bias)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Description of the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis. Details of whether attrition and exclusions were reported, the numbers in each intervention group (compared with total randomised participants), reasons for attrition/exclusions where reported, and any re‐inclusions in analyses performed by the review authors </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Were incomplete outcome data adequately addressed?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Selective outcome reporting</b> </p> <p><b>(reporting bias)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Details of how the possibility of selective outcome reporting was examined by the review authors, and what was found </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Are reports of the study free of the suggestion of selective outcome reporting?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other potential sources of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any important concerns about bias not addressed in the other risk of bias domains.</p> <p>If particular questions or entries were prespecified in the protocol of the review, responses should be provided for each question or entry. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Did the study appear to be free of other problems that could put it at high risk of bias? </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD008190-sec-0046"> <h4 class="title">Measures of treatment effect</h4> <p>We conducted the primary analysis using the Cochrane software Review Manager Web (<a href="./references#CD008190-bbs2-0149" title="Review Manager (RevMan Web). Version 4.13.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>). We measured any treatment effects for dichotomous data using the odds ratio (OR) and 95% confidence intervals (CIs). We measured any treatment effects for continuous data by analysing the mean changes from baseline measures and their standard deviations (SDs) to calculate the difference in means (MD) and their 95% CIs. </p> <p>Originally, we planned that if studies measured data longitudinally, we would base the analysis on the final time point results, since methods are not yet available to carry out a meta‐analysis of aggregate longitudinal data, unless individual patient data (IPD) are available (<a href="./references#CD008190-bbs2-0140" title="JonesAP , RileyR , WilliamsonPR , WhiteheadA . Meta-analysis of longitudinal data. In: Royal Statistical Society Annual Conference; 2005 Jul 18-21; Cardiff, UK. 2005.">Jones 2005</a>). However, when completing the data analysis, we decided to present all available data at selected time points separately. Trial investigators measured data longitudinally in one included trial of MA (<a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>); we reported data at each time point independently and did not combine these. </p> </section> <section id="CD008190-sec-0047"> <h4 class="title">Unit of analysis issues</h4> <p>When conducting the meta‐analysis combining results from cross‐over trials, we used the methods recommended by Elbourne (<a href="./references#CD008190-bbs2-0127" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , VailA . Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31(1):140-9.">Elbourne 2002</a>). Where individual data are available, the within‐participant changes and variation can be calculated directly, and we were able to include data from both arms of the trial. If we needed to combine data from cross‐over trials with data from parallel trials in a meta‐analysis, we used the weighted mean difference method discussed by Curtin (<a href="./references#CD008190-bbs2-0123" title="CurtinF , AltmanDG , ElbourneE . Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes. Statistics in Medicine2002;21(15):2131-44.">Curtin 2002a</a>; <a href="./references#CD008190-bbs2-0124" title="CurtinF , AltmanDG , ElbourneE . Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes. Statistics in Medicine2002;21(15):2145-59.">Curtin 2002b</a>; <a href="./references#CD008190-bbs2-0125" title="CurtinF , AltmanDG , ElbourneE . Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carryover. Statistics in Medicine2002;21(15):2161-73.">Curtin 2002c</a>), where the SDs entered into the meta‐analysis are adjusted to allow for within‐person correlations and produce the correct standard errors. </p> </section> <section id="CD008190-sec-0048"> <h4 class="title">Dealing with missing data</h4> <p>We described dropouts and the reasons given for them as provided in the primary papers. We contacted the original investigators if there were any missing data. </p> </section> <section id="CD008190-sec-0049"> <h4 class="title">Assessment of heterogeneity</h4> <p>We considered the extent to which results of trials were consistent using the Chi² test produced in the Review Manager Web forest plots, which assesses whether observed differences in results are compatible with chance alone. We also used the I² statistic; thresholds for the interpretation of I² were as follows: </p> <p> <ul id="CD008190-list-0008"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%:may represent considerable heterogeneity (<a href="./references#CD008190-bbs2-0136" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>) </p> </li> </ul> </p> </section> <section id="CD008190-sec-0050"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed publication bias by contacting the authors of trials assessed as awaiting classification to seek clarification on details of these studies (<a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>; <a href="./references#CD008190-bbs2-0056" title="KissnerDG . Role of progestational agents in the treatment of undernourished patients with cystic fibrosis. Pediatric Pulmonology2000;29(3):244. ">Kissner 2000</a>). Whilst we originally planned to assess the existence of publication bias from the meta‐analyses by a funnel plot, an insufficient number of trials combined (minimum of 10 required) precluded this. Furthermore, we acknowledge that the reasons for funnel plot asymmetry extend beyond reporting bias alone, for example methodological differences or pure chance. </p> <p>We assessed outcome reporting bias by obtaining data from the clinical trial registry, or by comparing the methods and results sections of the full publications and using knowledge of the clinical area. If we suspected outcome reporting bias, we contacted the trial investigators firstly to ascertain if they had measured and analysed the outcome, and secondly to obtain the data. </p> </section> <section id="CD008190-sec-0051"> <h4 class="title">Data synthesis</h4> <p>We used a fixed‐effect model in the analyses. We planned to use a random‐effects model if we identified at least moderate heterogeneity (e.g. I² value at least 30% to 60%) (<a href="./references#CD008190-bbs2-0136" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>). We considered and presented different interventions separately to identify their individual effects. </p> </section> <section id="CD008190-sec-0052"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned that if we identified clinical and statistical heterogeneity, and there were enough trials (at least 10) with sufficient published or reported details to permit the extraction of data for separate participant types, we would undertake subgroup analyses to investigate the following: </p> <p> <ol id="CD008190-list-0009"> <li> <p>level of disease severity (assessed by FEV<sub>1</sub> % predicted, <a href="./references#CD008190-bbs2-0147" title="PellegrinoR , ViegiG , BrusascoV , CrapoRO , BurgosF , CasaburiR , et al. Interpretative strategies for lung function tests. European Respiratory Journal2005;26(5):948-68.">Pellegrino 2005</a>, and BMI classification, <a href="./references#CD008190-bbs2-0017" title="CF Trust Nutrition Working Group. Appetite. In: Nutritional Management of Cystic Fibrosis: a Consensus Report. Bromley, UK: UK CF Trust, 2002:13. [ISBN 0-9540536-5-6]">CF Trust 2002</a>); </p> </li> <li> <p>different appetite stimulants;</p> </li> <li> <p>dosage of appetite stimulants.</p> </li> </ol> </p> <p>Whilst we were able to include several trials in the review, no single meta‐analysis combined a sufficient number of data sets to permit a subgroup analysis to investigate heterogeneity. </p> </section> <section id="CD008190-sec-0053"> <h4 class="title">Sensitivity analysis</h4> <p>There were insufficient trials combined within any single meta‐analysis to justify the use of a sensitivity analysis. If there are sufficient trials combined in future updates of this review, we will analyse data combining and splitting cross‐over and parallel trials to test if the current findings are robust. </p> </section> <section id="CD008190-sec-0054"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>In a post hoc change to the protocol, we generated a summary of findings (GRADE) table to rate the certainty of evidence for change in body weight (<a href="./references#CD008190-bbs2-0117" title="BalshemH , HelfandM , SchünemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE Guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401-6.">Balshem 2011</a>). We assessed the following outcomes in the table: </p> <p> <ol id="CD008190-list-0010"> <li> <p>change in weight (kg) at three months;</p> </li> <li> <p>change in weight (kg) at six months;</p> </li> <li> <p>change in weight (z score) at three months;</p> </li> <li> <p>change in weight (z score) at six months;</p> </li> <li> <p>change in FEV<sub>1</sub> % predicted at six months; </p> </li> <li> <p>change in appetite at three months.</p> </li> </ol> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008190-sec-0055" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008190-sec-0055"></div> <section id="CD008190-sec-0056"> <h3 class="title">Description of studies</h3> <section id="CD008190-sec-0057"> <h4 class="title">Results of the search</h4> <p>The combined searches identified a total of 179 titles and abstracts. Of these, 167 references (109 individual trials) were excluded from the review. There are no trials awaiting classification, and one trial is currently in progress. We included 11 references to four trials in the review. Please see the figures for a PRISMA diagram relating to the 2022 update only (<a href="#CD008190-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD008190-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram (2022 update)." data-id="CD008190-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_n/nCD008190-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram (2022 update).</p> </div> </div> </div> </section> <section id="CD008190-sec-0058"> <h4 class="title">Included studies</h4> <p>We included four RCTs, with a total of 70 participants, that addressed the use of potential appetite stimulants in children and adults with CF (<a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>; <a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>; <a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>; <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>). </p> <section id="CD008190-sec-0059"> <h5 class="title">Trial design</h5> <p>Three trials were conducted in the USA (<a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>; <a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>; <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>), and one in Brazil (<a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>). One trial had a cross‐over design (<a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>), whilst the remaining three trials had a parallel design (<a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>; <a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>; <a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>). We combined data from parallel and cross‐over trials using adjusted SDs (<a href="./references#CD008190-bbs2-0123" title="CurtinF , AltmanDG , ElbourneE . Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes. Statistics in Medicine2002;21(15):2131-44.">Curtin 2002a</a>; <a href="./references#CD008190-bbs2-0124" title="CurtinF , AltmanDG , ElbourneE . Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes. Statistics in Medicine2002;21(15):2145-59.">Curtin 2002b</a>; <a href="./references#CD008190-bbs2-0125" title="CurtinF , AltmanDG , ElbourneE . Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carryover. Statistics in Medicine2002;21(15):2161-73.">Curtin 2002c</a>). Trials varied in duration from three months, <a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>, to six months, <a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>. </p> </section> <section id="CD008190-sec-0060"> <h5 class="title">Participants</h5> <p>One trial recruited only children, including pre‐pubertal children (<a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>); one trial recruited children and adolescents (<a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>); and the remaining two trials included both children and adults (<a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>; <a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>). All trials reported the gender split between females and males (<a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>; <a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>; <a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>; <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>). Male‐to‐female ratios differed across trials: 14 males to 11 females in <a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>; 8 males to 9 females in <a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>; 6 males to 10 females in <a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>; and 3 males to 9 females in <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>. </p> </section> <section id="CD008190-sec-0061"> <h5 class="title">Interventions</h5> <p>Two trials evaluated MA (<a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>; <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>), and two trials evaluated CH (<a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>; <a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>). The dosage of oral appetite stimulants varied across trials; in two trials, MA was administered at a dose of 10 mg/kg/day (<a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>; <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>); in one trial, CH was administered at a dose of 4 mg four times daily (<a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>); and in the final study, CH was administered as 2 mg three times a day for one week, then 4 mg three times a day for 11 weeks (<a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>). All trials used a placebo as the comparator (<a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>; <a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>; <a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>; <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>). </p> </section> <section id="CD008190-sec-0062"> <h5 class="title">Outcomes</h5> <p>All four trials reported on change in body weight, change in pulmonary function, and adverse events (<a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>; <a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>; <a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>; <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>). Three trials reported on change in body composition (<a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>; <a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>; <a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>); two trials reported on change in appetite (<a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>; <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>); and two trials reported on change of dietary intake (<a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>; <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>). One trial reported on change in the number of pulmonary exacerbations (<a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>), and two trials reported on change in QoL (<a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>; <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>); one of these studies reported on QoL in the results section of the paper even though this was not stated in the methods section of the paper (<a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>). </p> </section> </section> <section id="CD008190-sec-0063"> <h4 class="title">Excluded studies</h4> <p>We excluded a total of 109 studies (168 references) from the review. Forty‐eight studies were not RCTs or quasi‐RCTs (<a href="./references#CD008190-bbs2-0006" title="AlemzadehR , UpchurchL , McCarthyV . Anabolic effects of growth hormone treatment in young children with cystic fibrosis. Journal of the American College of Nutrition1998;17(5):419-24. ">Alemzadeh 1998</a>; <a href="./references#CD008190-bbs2-0007" title="AmorimPG , deBarros MendesT , deOliveiraLSP , Guerra-JuniorG , RibeiroJD . Growth hormone in children and adolescents with cystic fibrosis [Hormonio de crescimento em criancas e adolescentes com fibrose cistica]. Arquivos Brasileiros de Endocrinologia e Metabologia2011;55(9):671-6 . ">Amorim 2011</a>; <a href="./references#CD008190-bbs2-0008" title="AnsteadMI , KuhnRJ , MartynD , CraigmyleL , KangaJF . Dronabinol, an effective and safe appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. ">Anstead 2003</a>; <a href="./references#CD008190-bbs2-0012" title="BattersbyR , PhillipsD , Van Der HaakN , MartinJ , TaiA . Retrospective audit of nutritional status of paediatric cystic fibrosis patients. Pediatric Pulmonology2017;52 Suppl 47:456-7. ">Battersby 2017</a>; <a href="./references#CD008190-bbs2-0016" title="CanfieldTM . The effect of megestrol on nutritional status in patients with cystic fibrosis. Pediatric Pulmonology1998;26 Suppl 17:359. ">Canfield 1998</a>; <a href="./references#CD008190-bbs2-0019" title="ChungSH , StenvinkelP , LindholmB , AvesaniCM . Identifying and managing malnutrition stemming from different causes. Peritoneal Dialysis International2006;27(Suppl 2):S239-44. ">Chung 2006</a>; <a href="./references#CD008190-bbs2-0020" title="ClaesI , Van MeerbeeckS , HavermansT , ProesmansM . Successful trial with an appetite stimulator in 2 siblings with cystic fibrosis with persistent failure to thrive and poor appetite. Journal of Cystic Fibrosis2020;19 Suppl 2:S137. ">Claes 2020</a>; <a href="./references#CD008190-bbs2-0021" title="CohenRI , TsangD , KoenigS , WilsonD , McCloskeyT , ChandraS . Plasma ghrelin and leptin in adult cystic fibrosis patients. Journal of Cystic Fibrosis2008;7(5):398-402. ">Cohen 2008</a>; <a href="./references#CD008190-bbs2-0022" title="CohenRI , ChandraS , KoenigS , TsangD , WilsonD , McCloskeyT . Ghrelin receptor expression in lymphocytes isolated from adult cystic fibrosis patients. Respiration2010;79(2):141-6. ">Cohen 2010</a>; <a href="./references#CD008190-bbs2-0024" title="CrawleyJ , PandyaS , LedsonMJ , WalshawMJ . Use of megestrol acetate to improve body weight in malnourished adult cystic fibrosis patients. Journal of Cystic Fibrosis2003;2 Suppl 1:S86, Abstract no. 336. ">Crawley 2003</a>; <a href="./references#CD008190-bbs2-0025" title="DarmaunD , HayesV , SchaefferD , WelchS , MaurasN . Effects of glutamine and recombinant human growth hormone on protein metabolism in prepubertal children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2004;89(3):1146-52. SchaefferD , DarmaunD , PunatiJ , MaurasN , HayesVY . Use of glutamine and recombinant human growth hormone in children with cystic fibrosis. Pediatric Pulmonology2000;30 Suppl 20:323. ">Darmaun 2004</a>; <a href="./references#CD008190-bbs2-0027" title="DhilloWS . Appetite regulation: an overview. Thyroid2007;17(5):433-45. ">Dhillo 2007</a>; <a href="./references#CD008190-bbs2-0029" title="DowsettJ . The use of megestrol acetate in the treatment of cachexia associated with cystic fibrosis [abstract]. Netherlands Journal of Medicine1999;54(Suppl):S83-4. ">Dowsett 1999</a>; <a href="./references#CD008190-bbs2-0031" title="DurantM , FarmerG . Megesterol acetate: treatment of growth failure in children with cystic fibrosis [abstract]. Pediatric Pulmonlogy1998;26 Suppl 17:360. ">Durant 1998</a>; <a href="./references#CD008190-bbs2-0032" title="EubanksV , WooldridgeN , ClancyJP , SorscherE , LyreneR , MakrisC . Megesterol acetate effects on weight in CF subject exhibiting growth failure: a case controlled study [abstract]. Pediatric Pulmonology1998;26 Suppl 17:360. ">Eubanks 2000</a>; <a href="./references#CD008190-bbs2-0037" title="GreenHD , BarryPJ , JonesAM . Anabolic agent use in adults with cystic fibrosis. Paediatric Respiratory Reviews2015;16 Suppl 1:28-30. ">Green 2015</a>; <a href="./references#CD008190-bbs2-0039" title="GrunertJ , van derHaakN , La VandaC , FarrowN , TaiA . Use of an appetite stimulant (Periactin) in paediatric patients with cystic fibrosis. Journal of Cystic Fibrosis2020;19 Suppl 2:S134. ">Grunert 2020</a>; <a href="./references#CD008190-bbs2-0040" title="GuillotMV , DesforgesAS , Voisin-ChiretAS , SchumannP , LaunayA , LecomteC . Evaluating the use of megesterol acetate in Caen and Lisieux CF Centers. Journal of Cystic Fibrosis2011;10(1):7. ">Guillot 2011a</a>; <a href="./references#CD008190-bbs2-0041" title="GuillotMV , DesforgesAS , Voisin-ChiretAS , SchumannP , LaunayA , LecomteC . Evaluating the use of megestrol acetate in Caen and Lisieux CF Centers (2007-2010). Journal of Cystic Fibrosis2011;10 Suppl 1:S75. ">Guillot 2011b</a>; <a href="./references#CD008190-bbs2-0042" title="HardinDS , SyJP . Effects of growth hormone treatment in children with cystic fibrosis: The National Cooperative Growth Study experience. Journal of Pediatrics1997;131(1 Pt 2):S65-9. ">Hardin 1997</a>; <a href="./references#CD008190-bbs2-0044" title="HardinDS , RiceJ , RosenblattR . Use of growth hormone in adults with CF. Pediatric Pulmonology2004;38 Suppl 27:343. ">Hardin 2004</a>; <a href="./references#CD008190-bbs2-0049" title="HardinDS . A review of the management of two common clinical problems found in patients with cystic fibrosis: cystic fibrosis-related diabetes and poor growth. Hormone Research2007;68(Suppl 5):113-6. ">Hardin 2007</a>; <a href="./references#CD008190-bbs2-0056" title="KissnerDG . Role of progestational agents in the treatment of undernourished patients with cystic fibrosis. Pediatric Pulmonology2000;29(3):244. ">Kissner 2000</a>; <a href="./references#CD008190-bbs2-0057" title="LeTN , AnabtawiA , PutmanMS , TangprichaV , StalveyMS . Growth failure and treatment in cystic fibrosis. Journal of Cystic Fibrosis2019;18 Suppl 2:S82-7. ">Le 2019</a>; <a href="./references#CD008190-bbs2-0058" title="LeungDH . The gastroenterologist approach to growth in CF. Pediatric Pulmonology2019;54 Suppl 2:113-5. ">Leung 2019</a>; <a href="./references#CD008190-bbs2-0064" title="McLearn-MontzAJ , SinghSB , Larson OdeK , FischerAJ . Linear growth in children receiving ivacaftor or ivacaftor-lumacaftor for cystic fibrosis. Pediatric Pulmonology2018;53 Suppl 2:386. ">McLearn‐Montz 2018</a>; <a href="./references#CD008190-bbs2-0068" title="NasrSZ , HurwitzM , BrownRW , EighorouryM , RosenD . Treatment of anorexia and weight loss with megesterol acetate in patients with cystic fibrosis. Pediatric Pulmonolgy1999;28(5):380-2. ">Nasr 1999</a>; <a href="./references#CD008190-bbs2-0069" title="NasrSZ , DruryD . Appetite stimulants use in cystic fibrosis. Pediatric Pulmonology2008;43(3):209-19. ">Nasr 2008</a>; <a href="./references#CD008190-bbs2-0070" title="NasrallahH . A review of the effect of atypical antipsychotics on weight. Psychoneuroendrocrinology2003;28:83-96. ">Nasrallah 2003</a>; <a href="./references#CD008190-bbs2-0077" title="NewkirkM , MartineJC , EwigJ , KrisemanT , GondorM , FarielloA . Adrenal suppression in children with cystic fibrosis treated with megesterol acetate [abstract]. Pediatric Pulmonology2000;30 Suppl 20:323. ">Newkirk 2000</a>; <a href="./references#CD008190-bbs2-0081" title="OhnhausEE , NueschE . Lack of effect of the appetite stimulant pizotifen on the absorption of isonicotinylhydrazine. European Journal of Clinical Pharmacology1974;7(1):59-60. ">Ohnhaus 1974</a>; <a href="./references#CD008190-bbs2-0083" title="ParsonsB , AllisonDB , LoebelA , WilliamsK , GillerE , RomanoS , et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophrenia Research2009;110:103-10. ">Parsons 2009</a>; <a href="./references#CD008190-bbs2-0084" title="PatersonI , TaylorM , RossE , BicknellS , MacGregorG . Promoting weight gain with olanzapine in underweight adults with cystic fibrosis [abstract]. Journal of Cystic Fibrosis2010;9 Suppl 1:S90, Abstract no. 349. ">Paterson 2010</a>; <a href="./references#CD008190-bbs2-0085" title="PhungOJ , ColemanCI , BakerEL , ScholleJM , GirottoJE , MakanjiSS , et al. Recombinant human growth hormone in the treatment of patients with cystic fibrosis. Pediatrics2010;125(5):e1211-26. ">Phung 2010</a>; <a href="./references#CD008190-bbs2-0086" title="PriceM , WatsonD . Evaluation of the use of megestrol acetate (MA) in adults with cystic fibrosis (CF). Journal of Cystic Fibrosis2016;15 Suppl 1:S102. ">Price 2016</a>; <a href="./references#CD008190-bbs2-0089" title="RossE , DavidsonS , SriramS , HempseyS , JaneY , MargaretK , et al. Weight gain associated with low dose olanzapine therapy in severely underweight adults with cystic fibrosis. Pediatric Pulmonology2005;40:350. ">Ross 2005</a>; <a href="./references#CD008190-bbs2-0090" title="SackeyAH , TaylorCJ , BarracloughM , WalesJKH , PickeringM . Growth hormone as a nutritional adjunct in cystic fibrosis: results of a pilot study. Journal of Human Nutrition and Dietetics1995;8:185-91. ">Sackey 1995</a>; <a href="./references#CD008190-bbs2-0096" title="StalveyMS , TorrezDM , HillanJ , Gonzalez-Peralta, HaafizA , RosenbloomAL . Growth hormone therapy improves growth in children with cystic fibrosis-related liver disease. Journal of Pediatric Endocrinology and Metabolism2008;21(8):793-7. ">Stalvey 2008</a>; <a href="./references#CD008190-bbs2-0098" title="StylianouC , Galli-TsinopoulouA , KoliakosG , FotoulakiM , Nousia-ArvanitakisS . Ghrelin and leptin levels in young adults with cystic fibrosis: relationship with body fat. Journal of Cystic Fibrosis2007;6(4):293-6. ">Stylianou 2007</a>; <a href="./references#CD008190-bbs2-0099" title="SullivanJS , MascarenhasMR . Nutrition: prevention and management of nutritional failure in cystic fibrosis. Journal of Cystic Fibrosis2017;16 Suppl 2:S87-93. ">Sullivan 2017</a>; <a href="./references#CD008190-bbs2-0100" title="SwitzerM , RiceJ , RiceM , HardinDS . Insulin-like growth factor-1 levels predict weight, height and protein catabolism in children and adolescents with cystic fibrosis. Journal of Pediatric Endocrinology and Metabolism2009;22(5):417-24. ">Switzer 2009</a>; <a href="./references#CD008190-bbs2-0101" title="SykesR , KittellF , MarcusM , TarterE , SchrothM . Mirtazapine for appetite stimulation in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 Suppl 29:389. ">Sykes 2006</a>; <a href="./references#CD008190-bbs2-0102" title="TaylorAM ,  BushA ,  ThomsonA ,  OadesPJ ,  MarchantJL ,  Bruce-MorganC , et al. Relation between insulin-like growth factor-I, body mass index and clinical status in cystic fibrosis. Archives of Disease in Childhood1997;76(4):304-9. ">Taylor 1997</a>; <a href="./references#CD008190-bbs2-0105" title="TongudaiS , BravermanS , KirkpatrickJA , HuangNN . Evaluation of oxandrolone in patients with cystic fibrosis. In: 12th Annual Meeting Cystic Fibrosis Club Abstracts; 1971 Apr 28; Atlantic City (NJ). 1971:54. ">Tongudai 1971</a>; <a href="./references#CD008190-bbs2-0107" title="Van MeerbeeckS , ProesmansM , BrantsJ , HavermansT , ClaesI , DupontL . Investigation of cyproheptadine as an appetite stimulator in 6 children with cystic fibrosis with a suboptimal nutritional status. Journal of Cystic Fibrosis2021;20 Suppl 1:S91. ">Van Meerbeeck 2021</a>; <a href="./references#CD008190-bbs2-0108" title="VarnessT , SeffroodEE , ConnorEL , RockMJ , AllenDB . Oxandrolone improves height velocity and BMI in patients with cystic fibrosis. International Journal of Pediatric Endocrinology 2010 Jan 24 [Epub ahead of print]. [DOI: 10.1155/2009/826895]">Varness 2009</a>; <a href="./references#CD008190-bbs2-0111" title="vonHaehlingS , LainscakM , SpringerJ , AnkerSD . Cardiac cachexia: a systematic overview. Pharmacology &amp; Therapeutics2009;121(3):227-52. ">von Haehling 2009</a>; <a href="./references#CD008190-bbs2-0113" title="YoungJ , DanduranMJ , McColleySA , BoarSR . The role of mirtazapine as an appetite stimulant in malnourished individuals with CF [abstract]. Pediatric Pulmonology2000;30 Suppl 20:326. ">Young 2000</a>); one study was a retrospective analysis of medical records (<a href="./references#CD008190-bbs2-0047" title="HardinDS , FerkolT , AhnC , DreimaneD , DysonM , MorseM , et al. A retrospective study of growth hormone used in adolescents with cystic fibrosis. Clinical Endocrinology2005;62(5):560-6. ">Hardin 2005c</a>); and one study was a consensus document (<a href="./references#CD008190-bbs2-0017" title="CF Trust Nutrition Working Group. Appetite. In: Nutritional Management of Cystic Fibrosis: a Consensus Report. Bromley, UK: UK CF Trust, 2002:13. [ISBN 0-9540536-5-6]">CF Trust 2002</a>). One study, identified at ClinicalTrials.gov, was terminated early after recruitment of only five participants, and no data were available (<a href="./references#CD008190-bbs2-0073" title="NCT00803179. Growth hormone therapy for wasting in cystic fibrosis. clinicaltrials.gov/ct2/show/NCT00803179 (first received 5 December 2008). ">NCT00803179</a>). Three papers were review articles (<a href="./references#CD008190-bbs2-0013" title="BerensteinG , OrtizZ . Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database of Systematic Reviews2005, Issue 2. Art. No: CD004310. [DOI: 10.1002/14651858.CD004310.pub2]">Berenstein 2005</a>; <a href="./references#CD008190-bbs2-0018" title="ChinuckRS , FortnumH , BaldwinDR . Appetite stimulants in cystic fibrosis: a systematic review. Journal of Human Nutrition and Dietetics2007;20(6):526-37. ">Chinuck 2007</a>; <a href="./references#CD008190-bbs2-0060" title="LópezAP , FigulsRM , CuchiGU , BerensteinEG , PasiesBA , AlegreMB , et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. Journal of Pain and Symptom Management2004;27(4):360-9. ">Lopez 2004</a>). In three studies participants were not diagnosed with CF or were not human (<a href="./references#CD008190-bbs2-0061" title="LoprinziCL , SchaidDJ , DoseAM , BurnhamNL , JensenMD . Body-composition changes in patients who gain weight while receiving megestrol acetate. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology1993;11(1):152-4. ">Loprinzi 1993</a>; <a href="./references#CD008190-bbs2-0087" title="RoganMP , ReznikovLR , PezzuloAA , GansemerND , SamuelM , PratherRS , et al. Pigs and humans with cystic fibrosis have reduced insulin-like growth factor (IGF1) levels at birth. Proceedings of the National Academy of Sciences of the United States of America2010;107(47):20571-5. ">Rogan 2010</a>; <a href="./references#CD008190-bbs2-0112" title="WeisbergJ , WangerJ , JefferyO , StritB , FogartyC , MartinT , et al. Megesterol acetate stimulates weight gain and ventilation in underweight COPD patients. Chest2002;121(4):1070-8. ">Weisberg 2002</a>). </p> <p>A total of 52 studies did not use the researching agent primarily as an appetite stimulant; they assessed the following: </p> <p> <ul id="CD008190-list-0011"> <li> <p>growth hormone therapy (14 studies) (<a href="./references#CD008190-bbs2-0015" title="BucuvalasJC , ChernausekSD , AlfaroMP , KrugS , RitschelW , WilmottRW . Insulin-like growth factor-1 enhances linear growth in undernourished prepubertal children with cystic fibrosis. Pediatric Pulmonology1998;26(Suppl 17):355. [CFGD REGISTER: GN123a] BucuvalasJC , ChernausekSD , AlfaroMP , KrugSK , RitschelW , WilmottRW . Effect of insulinlike growth factor-1 treatment in children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2001;33(5):576-81. [CFGD REGISTER: GN123b] ">Bucuvalas 2001</a>; <a href="./references#CD008190-bbs2-0043" title="HardinDS , EllisK , McConnellRA , SeilheimerDK . Growth hormone improves lean body mass in prepubertal CF children. Pediatric Pulmonology1998;26 Suppl 17:357. [CFGD REGISTER: GN122a] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone decreases protein catabolism in children with cystic fibrosis. Journal of Clinical Endocrinology and Metabolism2001;86(9):4424-8. [CFGD REGISTER: GN122d] HardinDS , EllisKJ , DysonM , RiceJ , McConnellR , SeilheimerDK . Growth hormone improves clinical status in prepubertal children with cystic fibrosis: results of a randomized controlled trial. Journal of Pediatrics2001;139(5):636-42. [CFGD REGISTER: GN122c] HardinDS , EllisKJ , McConnelR , SeilheimerDK . Growth hormone improves clinical status in cystic fibrosis children. Pediatric Pulmonology1999;28 Suppl 19:297. [CFGD REGISTER: GN122b] HardinDS , StrattonR , KramerJC , Reyes de la RochaS , GovaertsK , WilsonDP . Growth hormone improves weight velocity and height velocity in prepubertal children with cystic fibrosis. Hormone and Metabolic Research1998;30(10):636-41. NCT00256555. Growth hormone treatment study in children with cystic fibrosis. clinicaltrials.gov/ct2/show/NCT00256555 (first received 21 November 2005). [CFGD REGISTER: GN122e] ">Hardin 2001</a>; <a href="./references#CD008190-bbs2-0045" title="HardinDS , AhnC , PrestigeC , SeilheimerDK , EllisKJ . Growth hormone improves bone mineral content in children with cystic fibrosis. Journal of Pediatric Endocrinology and Metabolism2005;18(6):589-95. [CFGD REGISTER: GN126] ">Hardin 2005a</a>; <a href="./references#CD008190-bbs2-0046" title="HardinDS , RiceJ , AhnC , FerkolT , HowenstineM , SpearsS , et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. Journal of Pediatrics2005;146(3):324-8. [CFGD REGISTER: GN305] ">Hardin 2005b</a>; <a href="./references#CD008190-bbs2-0048" title="HardinD , RiceJ , AhnC , BrownD , ChatfieldB , DysonM , et al. Growth hormone improves bone mineralization in prepubertal children with CF - results of a multicenter study. Pediatric Pulmonology2004;38 Suppl 27:343, Abstract no. 438. [CFGD REGISTER: GN304c] HardinDS , Adams-HuetB , BrownD , ChatfieldB , DysonM , FerkolT , et al. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. Journal of Clinical Endocrinology and Metabolism2006;91(12):4925-9. [CFGD REGISTER: GN304d] HardinDS , ChatfieldB , DysonM , HicksD , HowenstineM , LeeP , et al. Multicentre trial of growth hormone in children with CF. Pediatric Pulmonology2001;32 Suppl 22:338. [CFGD REGISTER: GN304a] HardinDS , RiceJ , AhnC , ChatfieldB , DysonM , HowensteinM , et al. Growth hormone improves pulmonary function, weight, and height - results from a multicenter study. Pediatric Pulmonology2002;34 Suppl 24:337. [CFGD REGISTER: GN304b] ">Hardin 2006</a>; <a href="./references#CD008190-bbs2-0053" title="HusemanCA , ColomboJL , BrooksMA , SmayJR , GregerNG , SammutPH , et al. Anabolic effect of biosynthetic growth hormone in cystic fibrosis patients. Pediatric Pulmonology1996;22(2):90-5. ">Huseman 1996</a>; <a href="./references#CD008190-bbs2-0054" title="HütlerM , SchnabelD , StaabD , TackeA , WahnU , BöningD , et al. Effect of growth hormone on exercise tolerance in children with cystic fibrosis. Medicine and Science in Sports and Exercise2002;34(4):567-72. [CFGD REGISTER: GN125a] HutlerM , SchnabelD , StaabD , TackeA , WahnU , BoningD . Growth hormone enhances peak performance in cystic fibrosis. International Journal of Sports Medicine1998;19(Suppl):S17. [CFGD REGISTER: GN125b] ">Hutler 2002</a>; <a href="./references#CD008190-bbs2-0071" title="NCT00005112. Growth hormone use in cystic fibrosis - a multicenter study. clinicaltrials.gov/show/NCT00005112 (first received 17 April 2000). [CFGD REGISTER: GN302] ">NCT00005112</a>; <a href="./references#CD008190-bbs2-0072" title="NCT00016445. Phase II study of growth hormone in children with cystic fibrosis. clinicaltrials.gov/show/NCT00016445 (first received 7 May 2001). [CFGD REGISTER: GN303] ">NCT00016445</a>; <a href="./references#CD008190-bbs2-0093" title="SchiblerA , von derHeidenR , BirrerP , MullisPE . Moderate improved exercise capacity in patients with cystic fibrosis after treatment with recombinant human growth hormone. In: 12th European Respiratory Society Annual Congress; 2002 Sep 14-18; Stockholm, Sweden. 2002:P3287. SchiblerA , von derHeidenR , BirrerP , MullisPE . Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Archives of Disease in Childhood2003;88(12):1078-81. von derHeidenR , KraemerR , BirrerP , WaldeggG , MullisPE . Effect of growth hormone (r-hGH) treatment on working capacity, body composition, lung function and immunological parameters in patients with cystic fibrosis (CF). In: 21st European Cystic Fibrosis Conference; 1997 Jun 1-6; Davos, Switzerland. 1997:132. ">Schibler 2003</a>; <a href="./references#CD008190-bbs2-0094" title="GrasemannC , RatjenF , SchnabelD , ReutershahnE , VesterU , GrasemannH . Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients. European Respiratory Journal2008;4:815-21. GrasemannH , GrasemannC , SchnabelD , RatjenF . Growth hormone therapy results in increased L-arginine and nitrate concentrations in serum but decreased exhaled nitric oxide in patients with cystic fibrosis. Pediatric Pulmonology2006;41(S29):335. GrasemannH , GrasemannC , SchnabelF , RatjenF . Recombinant human growth hormone therapy results in increased systemic nitric oxide (NO) formation but decreased exhaled NO in patients with cystic fibrosis. In: American Thoracic Society 2006 International Conference; 2006 May 19‐24; San Diego, CA. 2006. [ABSTRACT NO.: A408p] SchnabelD , GrasemanC , StaabD , WollmanH , RatjenF , German Cystic Fibrosis Growth Hormone Study Group. A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Paediatrics2007;119(6):e1230-8. SchnabelD , GrasemannC , StaabD , WollmannH , RatjenF . A multicenter, randomized, double-blind placebo-controlled trial evaluating the metabolic and respiratory effects of growth hormone in children with cystic fibrosis [abstract]. Pediatric Pulmonology2006;41 Suppl 29:393. ">Schnabel 2007</a>; <a href="./references#CD008190-bbs2-0097" title="GellerDE , AnbarRD , KonstanMW , StalveyMS , JacobsJR , BakkerB . Growth hormone effects on pulmonary function in prepubertal children with cystic fibrosis [abstract]. Pediatric Pulmonology2008;43 Suppl 31:368. [CFGD REGISTER: GN128b] NCT00079742. A study to evaluate nutropin AQ for the treatment of growth restriction in children with cystic fibrosis. clinicaltrials.gov/show/NCT00079742 (first received 16 March 2004). [CFGD REGISTER: GN128d] StalveyMS , AnbarRD , KonstanMW , JacobsJR , BakkerB , LippeB , et al. A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatric Pulmonology2012;47(3):252-63. [CFGD REGISTER: GN128c] StalveyMS , GellerDE , AnbarRD , KonstanMW , JacobsJR , BakkerB . Growth hormone (GH) increases height, weight and lean body mass (LBM) in prepubertal children with cystic fibrosis (CF): results of a multicenter randomized control trial [abstract]. Pediatric Pulmonology2007;42 Suppl 30:393. [CFGD REGISTER: GN128a] ">Stalvey 2011</a>; <a href="./references#CD008190-bbs2-0104" title="ThakerV , CarterB , PutmanM . Recombinant growth hormone therapy for cystic fibrosis in children and young adults. Cochrane Database of Systematic Reviews2021, Issue 8. Art. No: CD008901. [DOI: 10.1002/14651858.CD008901.pub5]">Thaker 2013</a>; <a href="./references#CD008190-bbs2-0106" title="VanderwelM , HardinDS . Growth hormone normalizes pubertal onset in children with cystic fibrosis. Journal of Pediatric Endocrinology &amp; Metabolism2006;19(3):237-44. [CFGD REGISTER: GN297] ">Vanderwel 2006</a>); </p> </li> <li> <p>insulin therapy (10 studies) (<a href="./references#CD008190-bbs2-0010" title="BallmannM , HubertD , AssaelBM , KronfeldK , HonerM , HollRW , CFRD Study Group. Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus. BMC Pediatrics2014;14:70. [CFGD REGISTER: CO53c] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , Barao OcampoM , ScheunigN , et al. Repaglinide versus insulin in the treatment of CFRD diagnosed by screening: an open prospective randomized study [abstract]. Pediatric Pulmonology2013;48 Suppl 26:421, Abstract no. 582. [CENTRAL: 962122] [CFGD REGISTER: CO53b] BallmannM , HubertD , AssaelBM , Mosnier-PudarH , SmacznyC , KesslerL , et al. Treatment of early diagnosed CFRD with oral drugs versus insulin: an open prospective randomized study [abstract]. Journal of Cystic Fibrosis2013;12 Suppl 1:S32, Abstract no. WS16.1. [CENTRAL: 962115] [CFGD REGISTER: CO53a] BallmannM , HubertD , AssaelBM , StaabD , HebestreitA , NaehrlichL , et al. Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. Lancet Diabetes &amp; Endocrinology2018;6(2):114-21. [CFGD REGISTER: CO53e] Correction: repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial (Lancet Diabetes &amp; Endocrinology (2018) 6(2) (114–21), (S221385871730400X) (10.1016/S2213-8587(17)30400-X)). Lancet Diabetes &amp; Endocrinology2019;7(4):e4. [CFGD REGISTER: CO53f] [DOI: 10.1016/S2213-8587(17)30400-X)]NCT00662714. Early diagnosis of diabetes mellitus in patients with cystic fibrosis. clinicaltrials.gov/show/NCT00662714 (first received 21 April 2008). [CFGD REGISTER: CO53g] SchmidK , FinkK , HollRW , HebestreitH , BallmannM . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. Journal of Cystic Fibrosis2014;13(1):80-5. [CFGD REGISTER: CO53d] ">Ballmann 2013</a>; <a href="./references#CD008190-bbs2-0026" title="deLind van Wijngaarden-van den BergJM , van derMeerR , HeijermanHG . A placebo-controlled trial of insulin therapy with or without adjuvant metformin in patients with cystic fibrosis-related diabetes (CFRD). Journal of Cystic Fibrosis2014;13(Suppl 2):S12, Abstract no. WS6.4. [CFGD REGISTER: CO56] ">de Lind van Wijngaarden‐van den Berg 2014</a>; <a href="./references#CD008190-bbs2-0038" title="GroverP , ThomasW , MoranA . Glargine versus NPH insulin in cystic fibrosis related diabetes. Journal of Cystic Fibrosis2008;7(2):134-6. ">Grover 2008</a>; <a href="./references#CD008190-bbs2-0065" title="MinicucciL , CasciaroR , De AlessandriA , HauptM , CasoM , LucidiV , et al. Efficacy of slow release insulin in patients with cystic fibrosis and glucide intolerance [abstract]. Journal of Cystic Fibrosis2009;8 Suppl 2:S82, Abstract no. 331. [CFGD REGISTER: CO42b] MinicucciL , HauptM , CasciaroR , De AlessandriA , BagnascoF , LucidiV , et al. Slow-release insulin in cystic fibrosis patients with glucose intolerance: a randomized clinical trial. Pediatric Diabetes2012;13(2):197-202. [CFGD REGISTER: CO42c] MinicucciL . New diagnostic and therapeutic approaches in cystic fibrosis related diabetes (CFRD) [abstract]. Journal of Cystic Fibrosis2008;7 Suppl 3:S6, Abstract no. R25. [CFGD REGISTER: CO42a] ">Minicucci 2012</a>; <a href="./references#CD008190-bbs2-0066" title="MillaCE , PhillipsJ , MoranA . Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in CFRD. Pediatric Pulmonology2001;32 Suppl 22:335, Abstract no. 477. [CFGD REGISTER: CO34a] MoranA , PhillipsJ , MillaC . Insulin and glucose excursion following premeal insulin lispo or repaglinide in cystic fibrosis-related diabetes. Diabetes Care2001;24(10):1706-10. [CFGD REGISTER: CO34b] ">Moran 2001</a>; <a href="./references#CD008190-bbs2-0067" title="MoranA , PekowP , GroverP , ZornM , SlovisB , PilewskiJ , et al. Insulin therapy to improve BMI in cystic fibrosis related diabetes without fasting hyperglycemia: results of the CFRDT Trial. Diabetes Care2009;32(10):1783-8. [CFGD REGISTER: CO43] NCT00072904. Diabetes therapy to improve BMI and lung function in CF. clinicaltrials.gov/show/NCT00072904 (first received 14 November 2003). [CFGD REGISTER: CO43b] ">Moran 2009</a>; <a href="./references#CD008190-bbs2-0074" title="NCT01149005. Cystic fibrosis (CF) exacerbation and insulin treatment. clinicaltrials.gov/show/nct01149005 (first received 23 June 2010). ">NCT01149005</a>; <a href="./references#CD008190-bbs2-0095" title="SeggelkeSA , GibbsJ , DrazninB . Pilot study of using neutral protamine Hagedorn insulin to counteract the effect of methylprednisolone in hospitalized patients with diabetes. Journal of Hospital Medicine2011;6(3):175-6. [CFGD REGISTER: CO90] ">Seggelke 2011</a>; <a href="./references#CD008190-bbs2-0103" title="TeeterJG , The Exubera Phase 3 Study Group, Pfizer Global Research and Development GCU. One-year pulmonary safety and efficacy of inhaled insulin as adjunctive therapy in type 2 diabetes patients poorly controlled on oral agent monotherapy [abstract]. European Respiratory Journal2004;24(Suppl 48):P3773. ">Teeter 2004</a>; <a href="./references#CD008190-bbs2-0109" title="ACTRN12611000068965. CF-IDEA (cystic fibrosis - insulin deficiency, early action): randomised controlled trial of once-daily insulin detemir in patients with cystic fibrosis and early insulin deficiency. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000068965 (first received 19 January 2011). [CFGD REGISTER: CO89b] NCT01100892. Cystic Fibrosis - Insulin Deficiency, Early Action. clinicaltrials.gov/show/NCT01100892 (first received 9 April 2010). [CFGD REGISTER: CO89a] VergeC . Cystic Fibrosis - Insulin Deficiency, Early Action. Pediatric Diabetes2015;16 Suppl 21:15. [CFGD REGISTER: CO89c] ">Verge 2015</a>); </p> </li> <li> <p>zinc supplementation (1 study) (<a href="./references#CD008190-bbs2-0091" title="SafaiKS , SelinE , LarssonS , JagenburgR , DenforsI , StenG , et al. Zinc therapy in children with cystic fibrosis. Beitrage zur Infusiontherapie1991;27:104-14. ">Safai 1991</a>); </p> </li> <li> <p>prednisone therapy (8 studies) (<a href="./references#CD008190-bbs2-0009" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. [CFGD REGISTER: IB2b] DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis. Pediatric Pulmonology1990;9 Suppl 5:322. [CFGD REGISTER: IB2a] ">Auerbach 1985</a>; <a href="./references#CD008190-bbs2-0023" title="Cohen-CymberknohM , ShoseyovD , EfratiO , ArmoniS , KeremE . Intravenous methylprednisolone pulse therapy vs.oral prednisone for allergic bronchopulmonary aspergillosis (ABPA) in CF. Journal of Cystic Fibrosis2008;7 Suppl 2:S58. ">Cohen‐Cymberknoh 2008</a>; <a href="./references#CD008190-bbs2-0028" title="DoveyM , AikenML , EmersonJ , McNamaraS , WaltzDA , GibsonRL . Oral corticosteroids therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study. Chest2007;132(4):1212-8. DoveyM , AitkenML , EmersonJ , McNamaraS , DormanD , GibsonRL . A randomised, double-blind, placebo-controlled trial of oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbations [abstract]. Pediatric Pulmonology2004;38 Suppl 27:301. ">Dovey 2007</a>; <a href="./references#CD008190-bbs2-0036" title="GreallyP , HussainMJ , VerganiD , PriceJF . Interleukin-1 alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Archives of Disease in Childhood1994;71(1):35-9. GreallyP , SampsonAJ , PiperPJ , PriceJF . Effect of prednisolone on airways obstruction in patients with cystic fibrosis [abstract]. European Respiratory Journal1992;5(Suppl 15):259s. GreallyP , SampsonAP , PiperPJ , PriceJF . Prednisolone reduces airways obstruction in children with cystic fibrosis. In: 11th International Cystic Fibrosis Congress; 1992 Aug 22-27; Dubin, Ireland. 1992:TS12. ">Greally 1992</a>; <a href="./references#CD008190-bbs2-0059" title="LinnaneSJ , ThinAG , KeatingsVM , MoynihanJB , Mc LoughlinP , FitzgeraldMX . Glucocorticoid treatment reduces exhaled nitric oxide in cystic fibrosis patients. European Respiratory Journal2001;17(6):1267-70. ">Linnane 2001</a>; <a href="./references#CD008190-bbs2-0078" title="NyamugunduruG , DesaiM , RaynerRJ , SimmondsE , WellerPH , SpencerDA . A CFRD double-blind parallel placebo controlled randomised study of oral prednisolone in acute respiratory exacerbations in children with cystic fibrosis [abstract]. Thorax1998;53(Suppl 4):A61. NyamugunduruG , DesaiM , SpencerD , ClarkeJ , WellerP . A double-blind parallel placebo-controlled randomised study of the addition of short-course oral prednisolone in treatment of acute respiratory exacerbations in children with cystic fibrosis. In: 22nd European Cystic Fibrosis Conference; 1998 Jun 13-19; Berlin, Germany. 1998:79. NyamugunduruG , DesaiM , WellerPH , SpencerDA . The effect of oral prednisolone on serum interleukin-8 concentrations in acute respiratory exacerbations in children with cystic fibrosis. In: 13th International Cystic Fibrosis Congress; 2000 Jun 4-8; Stockholm, Sweden. 2000:183. ">Nyamugunduru 1998</a>; <a href="./references#CD008190-bbs2-0082" title="PantinF , SteadRJ , HodsonM , BattenJ . Prednisolone in the treatment of airflow obstruction in adults with cystic fibrosis. Thorax1986;41(1):34-8. SteadRJ , PantinCFA , HodsonME , BattenJC . Prednisolone in the treatment of airflow obstruction in adults with cystic fibrosis. In: 13th Annual Meeting of the European Working Group for Cystic Fibrosis; 1985 Nov 3-8; Jerusalem, Israel. 1985:112. ">Pantin 1986</a>; <a href="./references#CD008190-bbs2-0088" title="EigenH , RosensteinBJ , FitzSimmonsS , SchidlowDV . A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid therapy [abstract]. Pediatric Pulmonology1991;10 Suppl 6:313. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 Suppl 19:297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Rosenstein 1991</a>); </p> </li> <li> <p>carbohydrate counting (1 study) (<a href="./references#CD008190-bbs2-0035" title="GranciniV , GaglioA , ResiV , PalmieriE , OrsiE . Effectiveness of cho-counting on glycometabolic control and comparison between the methods of I/cho ratio calculation in subjects with cystic fibrosis-related diabetes (CFRD). Diabetes2019;68 Suppl 1:708-P. [CFGD REGISTER: CO80] ">Grancini 2019</a>); </p> </li> <li> <p>L‐glutathione (1 study) (<a href="./references#CD008190-bbs2-0110" title="ViscaA , HiltonSC , HudsonVM , BishopCT . Oral reduced L-glutathione improves weight and calprotectin in pediatric cystic fibrosis patients. Journal of Cystic Fibrosis2013;12 Suppl 1:S64. ">Visca 2013</a>); </p> </li> <li> <p>gene therapy (2 studies) (<a href="./references#CD008190-bbs2-0055" title="KingSJ , WilliamsE , KeatingD , KotsimbosT , ButtonBM , Allen-GrahamJ , et al. Patterns of change in body composition on treatment with lumacaftor-ivacaftor in severe cystic fibrosis lung disease: early gains in weight and fat mass plateau by one year. Pediatric Pulmonology2018;53 Suppl 2:394. ">King 2018</a>; <a href="./references#CD008190-bbs2-0092" title="SawickiGS , McKoneEF , PastaDJ , WagenerJ , JohnsonC , MillarSJ , et al. The effect of ivacaftor on weight over three years in patients with cf and a G551DCFTR mutation. Pediatric Pulmonology2014;49 Suppl 38:289. ">Sawicki 2014</a>); </p> </li> <li> <p>mental health or quality of life treatments such as behavioural therapy (14 studies) (<a href="./references#CD008190-bbs2-0005" title="ACTRN12619000572167. Improving mental health of young Australians with chronic illness: a pilot study of the effectiveness of online self-compassion training. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12619000572167 (first received 19 February 2019). [CFGD REGISTER: MH189] ">ACTRN12619000572167</a>; <a href="./references#CD008190-bbs2-0011" title="BathgateC , HolmK , MurphyN , KilbournK , WamboldtF . Coping and learning to manage stress in cystic fibrosis via telehealth: RCT pilot results. Pediatric Pulmonology2020;55 Suppl 2:261. [CFGD REGISTER: MH74b] BathgateC , HolmK , MurphyN , KilbournK , WamboldtF . Randomised controlled trial piloting the “Coping and Learning to Manage Stress in CF” (CALM) telehealth intervention to reduce depressive and anxious symptoms in adults with cystic fibrosis. Journal of Cystic Fibrosis2021;20 Suppl 1:S21. [CFGD REGISTER: MH74d] BathgateC , HolmK , MurphyN , KilbournK , WamboldtF . Telehealth cognitive behavioral stress management - preliminary pilot highlights and challenges. Pediatric Pulmonology2019;54 Suppl 2:411. [CFGD REGISTER: MH74a] NCT03560726. Telehealth cognitive behavioral stress management for adults with cystic fibrosis. clinicaltrials.gov/show/NCT03560726 (first received 18 June 2018). [CFGD REGISTER: MH74c] ">Bathgate 2019</a>; <a href="./references#CD008190-bbs2-0014" title="Branch-SmithC , BarrettA , BaldingE , GroverZ , YikilmazG , BourkeC , et al. Treating parents of children with cystic fibrosis with unresolved grief. Respirology2018;23(Suppl 1):138. [CFGD REGISTER: MH72] ">Branch‐Smith 2018</a>; <a href="./references#CD008190-bbs2-0030" title="DRKS00010979. Web-based psychological support program for parental caregivers of children with rare chronic diseases. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00010979 (first received 7 October 2016). [CFGD REGISTER: MH190] ">DRKS00010979</a>; <a href="./references#CD008190-bbs2-0033" title="DRKS00016714. Feasibility trial of an online intervention for symptoms of depression and anxiety in adolescents with chronic medical conditions (youthCOACH-CD). trialsearch.who.int/Trial2.aspx?TrialID=DRKS00016714 (first received 25 March 2019). [CFGD REGISTER: MH191a] GeirhosA , DomhardtM , LunkenheimerF , TemmingS , HollRW , MindenK , et al. Feasibility and potential efficacy of a guided internet- and mobile-based CBT for adolescents and young adults with chronic medical conditions and comorbid depression or anxiety symptoms (youthCOACHCD): a randomized controlled pilot trial. BMC Pediatrics2022;22(1):69. [CFGD REGISTER: MH191b] ">Geirhos 2022</a>; <a href="./references#CD008190-bbs2-0034" title="GoetzDM , RandK , RoachCM , CogswellA , SmithBA . Screening for depression in caregivers of children with cystic fibrosis. Pediatric Pulmonology2016;51 Suppl 45:456, Abstract no. 685. [CFGD REGISTER: PI12] ">Goetz 2016</a>; <a href="./references#CD008190-bbs2-0050" title="HiderA , NasrSZ , SamyaZ . Addressing nutritional failure in a cystic fibrosis patient using nutritional and psychological intervention. Clinical Nutrition ESPEN2020;40:336-9. ">Hider 2020</a>; <a href="./references#CD008190-bbs2-0051" title="BorschukAP , EverhartR , EakinMN , RiekertKA . Impact of disclosure to colleagues, friends and romantic partners on older adolescent and adult psychosocial outcome. Pediatric Pulmonology2015;50 Suppl 41:190-1. [CFGD REGISTER: MH51c] [SUMMARY NO.: S21.3]BorschukAP , EverhartRS , EakinMN , Rand-GiovannettiD , BorrelliB , RiekertKA . Disease disclosure in individuals with cystic fibrosis: association with psychosocial and health outcomes. Journal of Cystic Fibrosis2016;15(5):696-702. [CFGD REGISTER: MH51b] HilliardME , EakinMN , BorrelliB , GreenA , RiekertKA . Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis. Health Psychology2015;34(5):496-504. [CFGD REGISTER: MH51a] NCT01013896. Building adherence to live with and navigate my cystic fibrosis (CF) experience. clinicaltrials.gov/show/NCT01013896 (first received 16 November 2009). [CFGD REGISTER: MH51e] RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CFGD REGISTER: MH51d] [SUMMARY NO.: S7.1]RiekertKA , BorrelliB , BilderbackAV , GreenA , EakinMN . Building adherence to live and navigate my CF experience: the balance study. Pediatric Pulmonology2013;48 Suppl 36:133. [CFGD REGISTER: MH51d] [SUMMARY NO.: S7.1]">Hilliard 2015</a>; <a href="./references#CD008190-bbs2-0062" title="DRKS00017161. Effectiveness and cost-effectiveness of guided internet-and mobile-based CBT for adolescents and young adults with chronic somatic conditions and comorbid depression and anxiety symptoms (youthCOACHcd): a multicentre randomized controlled trial with a 12-month follow-up. trialsearch.who.int/Trial2.aspx?TrialID=DRKS00017161 (first received 17 September 2019). [CFGD REGISTER: MH179a] LunkenheimerF , DomhardtM , GeirhosA , KilianR , Mueller-StierlinAS , HollRW , et al. Effectiveness and cost-effectiveness of guided Internet- and mobile-based CBT for adolescents and young adults with chronic somatic conditions and comorbid depression and anxiety symptoms (youthCOACHCD): study protocol for a multicentre randomized controlled trial. Trials2020;21(1):253. [CFGD REGISTER: MH179b] LunkenheimerF , DomhardtM , GeirhosA , KilianR , Mueller-StierlinAS , HollRW , et al. Effectiveness and cost-effectiveness of guided Internet- and mobile-based CBT for adolescents and young adults with chronic somatic conditions and comorbid depression and anxiety symptoms (youthCOACHCD): study protocol for a multicentre randomized controlled trial. Trials2020;21(1):253. Online Supplementary Materials: Additional file 1 SPIRIT 2013 Checklist. [CFGD REGISTER: MH179c] ">Lunkenheimer 2020</a>; <a href="./references#CD008190-bbs2-0063" title="McLeanKA , MadanA , MonzonA , QuittnerAL . Trajectories of depression and anxiety in adolescents with CF. Pediatric Pulmonology2014;49 Suppl 38:442, Abstract no. 611. [CFGD REGISTER: MH43] ">McLean 2014</a>; <a href="./references#CD008190-bbs2-0075" title="NCT03139266. Project UPLIFT to reduce anxiety and depression in CF patients. clinicaltrials.gov/show/NCT03139266 (first received 3 May 2017). [CFGD REGISTER: MH192] ">NCT03139266</a>; <a href="./references#CD008190-bbs2-0076" title="NCT03800459. Effect of a family empowerment program on coping, problem solving in parents, and quality of life in children with cystic fibrosis. clinicaltrials.gov/show/NCT03800459 (first received 11 January 2019). [CFGD REGISTER: MH196] ">NCT03800459</a>; <a href="./references#CD008190-bbs2-0079" title="O'HayerCF , EdouardG , BennettDS , TaylorDN , Hem LeeMA , WolfeWM , et al. ACT via telehealth: acceptance-based behavioral therapy for anxiety and depression among individuals with cystic fibrosis. Pediatric Pulmonology2017;52 Suppl 47:476. [CFGD REGISTER: MH63] ">O'Hayer 2017</a>; <a href="./references#CD008190-bbs2-0080" title="NCT04114227. Acceptance and commitment therapy vs. supportive psychotherapy with cystic fibrosis patients. clinicaltrials.gov/show/NCT04114227 (first received 3 October 2019). [CFGD REGISTER: MH177c] O'HayerCF , SmithPJ , DrescherC , NurseCN , StephenMJ . Act with CF next directions: design of a multisite, randomized controlled trial of telehealth acceptance and commitment therapy vs supportive psychotherapy for anxiety and depression. Pediatric Pulmonology2019;54 Suppl 2:421. [CFGD REGISTER: MH177] O'HayerCV , O'LoughlinCM , NurseCN , SmithPJ , StephenMJ . ACT with CF: a telehealth and in-person feasibility study to address anxiety and depressive symptoms among people with cystic fibrosis. Journal of Cystic Fibrosis2021;20(1):133-9. [CFGD REGISTER: MH177b] ">O'Hayer 2019</a>); </p> </li> <li> <p>insomnia (1 study) (<a href="./references#CD008190-bbs2-0052" title="HjelmM , KowatchR , NemastilCJ , SliemersS , JacksonK , PasleyK , et al. Telephone cognitive behavioral therapy treatment of insomnia for people with cystic fibrosis: a pilot randomized trial. Pediatric Pulmonology2020;55(Suppl 2):263. [CFGD REGISTER: MH194] ">Hjelm 2020</a>).  </p> </li> </ul> </p> </section> <section id="CD008190-sec-0064"> <h4 class="title">Ongoing studies</h4> <p>One trial had no results published, and the trial registry entry has not been updated since 2010 (<a href="./references#CD008190-bbs2-0114" title="NCT00763477. Ghrelin in cystic fibrosis (ghrelin). clinicaltrials.gov/ct2/show/NCT00763477 (first received 1 October 2008). ">NCT00763477</a>). The principal investigator reports that they aim to publish results in the future.  </p> </section> </section> <section id="CD008190-sec-0065"> <h3 class="title">Risk of bias in included studies</h3> <p>Risk of bias in the included trials is summarised in a risk of bias graph and risk of bias summary (<a href="#CD008190-fig-0002">Figure 2</a>; <a href="#CD008190-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD008190-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008190-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_n/nCD008190-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD008190-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008190-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_n/nCD008190-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD008190-sec-0066"> <h4 class="title">Allocation</h4> <section id="CD008190-sec-0067"> <h5 class="title">Randomisation procedure</h5> <p>All included trials referred to random allocation, from briefly commenting that participants were randomised to providing a detailed description of the sequence generation. We judged the single trial that was described as randomised but which gave no details as having an unclear risk of bias (<a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>). The remaining three trials reported using a computer‐generated randomisation procedure (<a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>; <a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>), or more specifically SAS small block randomisation (<a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>), and were judged as having a low risk of bias. </p> </section> <section id="CD008190-sec-0068"> <h5 class="title">Allocation concealment</h5> <p>One trial reported storing the intervention in opaque envelopes (<a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>). None of the other included trials discussed the method of allocation concealment; we assessed these trials as at unclear risk of bias (<a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>; <a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>; <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>). </p> </section> </section> <section id="CD008190-sec-0069"> <h4 class="title">Blinding</h4> <p>Three trials were described as double‐blind (<a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>; <a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>; <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>), whilst the remaining trial stated that only the pharmacist investigator and trial co‐ordinator remained unblinded (<a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>). We judged all included trials as having a low risk of bias. </p> </section> <section id="CD008190-sec-0070"> <h4 class="title">Incomplete outcome data</h4> <p>We judged two trials to have a low risk of bias (<a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>; <a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>). In one of these trials, four out of 25 participants did not complete the trial (16% dropout rate), but there were equal numbers across groups, and the reasons for dropout were similar: one participant from each group withdrew due to non‐adherence; one participant withdrew from the intervention group because of an intolerance to CH; and one participant withdrew from the placebo group because of an allergy to the placebo (<a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>). A further trial had minimal dropouts, or dropouts that were unrelated to the intervention (<a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>).  </p> <p>We judged the two remaining trials to have a high risk of bias (<a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>; <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>). One trial had a dropout explicitly linked to the intervention (no effect in the placebo group), and there was no evidence of a treatment of the missing data to reduce the bias (<a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>). The second trial had a 50% dropout rate (six out of 12 participants), with the missing data being excluded and no clear evidence that bias was not introduced (<a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>). </p> </section> <section id="CD008190-sec-0071"> <h4 class="title">Selective reporting</h4> <p>In one trial, whilst there were no apparent differences between the methods and results sections, we could not be certain of this as the original paper was written in Portuguese, and we had no access to the trial protocol. We therefore judged this study to be at unclear risk of reporting bias (<a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>).  </p> <p>We assessed the risk of reporting bias in the other three included trials by comparing the published methods with the reported results (<a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>; <a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>; <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>). None of these trials appeared to be free from selective reporting, and were therefore judged to have a high risk of bias. The following outcomes were stated in the methods sections of the papers but not reported on in the results sections: dietary intake (<a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>), and dietary intake and pulmonary function (<a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>; <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>). In contrast, the following outcomes not stated in the methods sections were subsequently reported on in the results sections: dietary energy intake and spirometry (<a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>), and QoL (<a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>). In addition, outcomes stated in the methods section of <a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a> were reported using unexpected measures (i.e. weight for age z score only, instead of being additional to weight as a mean (SD)). Furthermore, Eubanks and colleagues reported LBM and fat mass for the MA group but not for the placebo group (<a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>). </p> </section> <section id="CD008190-sec-0072"> <h4 class="title">Other potential sources of bias</h4> <p><a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a> reported significant differences in FEV<sub>1</sub> % predicted between the placebo and CH groups at baseline: mean (SD) 42.3 (17.6) in the placebo group and 68.9 (28.1) in the CH group (P = 0.039). Allowing for an adjustment of the P value for testing multiple outcomes, the difference was not significant, and hence was not evidence for risk of bias. </p> <p>We identified no other potential sources of bias in the remaining trials (<a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>; <a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>; <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>). </p> </section> </section> <section id="CD008190-sec-0073"> <h3 class="title" id="CD008190-sec-0073">Effects of interventions</h3> <p>See: <a href="./full#CD008190-tbl-0001"><b>Summary of findings 1</b> Appetite stimulants versus placebo for people with cystic fibrosis</a> </p> <p>All four trials (70 participants) reported data for appetite stimulants versus control (<a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>; <a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>; <a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>; <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>). Two trials compared the effect of MA with placebo (<a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>; <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>), and two trials compared the effect of CH with placebo (<a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>; <a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>). Explanations for our assessment of the certainty of the evidence are provided in <a href="./full#CD008190-tbl-0001">summary of findings Table 1</a>.  </p> <section id="CD008190-sec-0074"> <h4 class="title">Primary outcomes</h4> <section id="CD008190-sec-0075"> <h5 class="title">1. Change in body weight (kg)</h5> <p>All four trials (70 participants) reported data for change in body weight (<a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>; <a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>; <a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>; <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>).  </p> <p>Two trials (42 participants), one of MA and one of CH, reported a change in weight at three months (<a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>; <a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>). Combined data showed that the appetite stimulant may lead to a greater weight gain compared with placebo (mean difference (MD) 1.25 kg, 95% confidence interval (Cl) 0.45 to 2.05) (<a href="./references#CD008190-fig-0004" title="">Analysis 1.1</a>) (low‐certainty evidence). Only one trial of MA (17 participants) reported on change in weight at six months (<a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>); similar to the earlier time point, the intervention may lead to a greater weight gain than the placebo (MD 3.80 kg, 95% CI 1.27 to 6.33) (<a href="./references#CD008190-fig-0004" title="">Analysis 1.1</a>) (low‐certainty evidence). </p> <p>Three trials (45 participants) reported that appetite stimulants may lead to a greater change in weight z score (WAZ) at three months (<a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>; <a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>; <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>); combined results were statistically significant (MD 0.61, 95% CI 0.29 to 0.93) (P &lt; 0.001) (<a href="./references#CD008190-fig-0005" title="">Analysis 1.2</a>). We assessed the certainty of the evidence as low, and heterogeneity was low (I² = 0%) (<a href="./references#CD008190-fig-0005" title="">Analysis 1.2</a>). In one cross‐over trial (12 participants), individual patient data for WAZ score were available from a graph (<a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>), therefore the within‐participant variation could be calculated, and the meta‐analysis carried out using the methodology of Elbourne with the paired participant intervention and control periods used as the unit of analysis (<a href="./references#CD008190-bbs2-0127" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , VailA . Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31(1):140-9.">Elbourne 2002</a>). Only <a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a> (17 participants) reported WAZ at six months, with similar results to the three‐month data (MD 0.74, 95% CI 0.26 to 1.22) (<a href="./references#CD008190-fig-0005" title="">Analysis 1.2</a>) (low‐certainty evidence); the same trial also presented results for one and two months on a graph, but not in the text or tables, with the WAZ effect size and standard error similar to the three‐month value (<a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>). </p> <p>The subgroup analysis of three‐month data for WAZ by appetite stimulant did not provide any evidence for different effects of MA and CH on weight gain (test for subgroup difference Chi² = 0.04, df = 1, P = 0.84; I² = 0%), with both subgroups showing a significant weight gain: MA 0.68 (95% CI 0.24 to 1.13) (P = 0.003) and CH 0.62 (95% CI 0.21 to 1.03) (P = 0.003) (<a href="./references#CD008190-fig-0006" title="">Analysis 1.3</a>). </p> <p>In the nine‐month paediatric trial (12 participants), <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a> reported the "average" change in weight with ranges, therefore data could not be entered into the analysis; investigators observed an "average" weight gain of 3.05 kg in the MA group (range 0.1 kg to 7.0 kg) versus 0.3 kg in the placebo group (range −0.3 kg to 0.8 kg); this was significant (P = 0.04) (<a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>). </p> </section> <section id="CD008190-sec-0076"> <h5 class="title">2. Change in body composition</h5> <section id="CD008190-sec-0077"> <h6 class="title">a. Lean body mass (LBM)</h6> <p>None of the trials reported change in LBM in sufficient detail to permit inclusion in a meta‐analysis, and no further data were obtained from the investigators when contacted. </p> <p>In the original paper, <a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a> (17 participants) reported significant increases in triceps skin‐fold measurements and mid‐arm circumference in the treatment group at three and six months (P &lt; 0.01); further data were not available for analysis in this review. <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a> (12 participants) also reported an improvement in LBM in the group receiving MA. </p> </section> <section id="CD008190-sec-0078"> <h6 class="title">b. Fat mass</h6> <p>Likewise, none of the trials reported change in fat mass in sufficient detail to permit inclusion in a meta‐analysis. </p> <p>In the original paper, <a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a> (17 participants) reported an increase in both fat mass and fat‐free mass in the MA group, assessed by dual‐energy X‐ray absorptiometry (DEXA) (P &lt; 0.02, at three and six months); further data were not available for analysis in this review. <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a> (12 participants) also reported an improvement in body fat in the MA group. In the 2004 trial, Homnick (16 participants) reported a significant increase in fat and fat‐free mass in the CH group over 12 weeks (<a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>). </p> </section> <section id="CD008190-sec-0079"> <h6 class="title">c. Body mass index (BMI)</h6> <p>Homnick (16 participants) also reported a significant increase in BMI in the group receiving CH, and no significant change in BMI for the placebo group (<a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>); however, variation of the change in BMI was not given, and no direct comparison between groups was carried out. </p> <p><a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a> (25 participants) reported an increase in BMI in the intervention group and a decrease in the control group; when analysed the data favoured appetite stimulants (MD 0.53, 95% CI 0.07 to 0.99) (<a href="./references#CD008190-fig-0007" title="">Analysis 1.4</a>). </p> </section> </section> <section id="CD008190-sec-0080"> <h5 class="title">3. Change in pulmonary function</h5> <p>Whilst a change in lung function is a primary outcome measure of appetite stimulant use, it is important to highlight that the included trials were not performed to directly affect pulmonary function; the use of appetite stimulants may take longer to show an improvement in respiratory muscle function than any of the trials reviewed and included. The effect of MA, <a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>; <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>, and CH, <a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>; <a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>, compared with placebo on change in pulmonary function was reported in children and adults. </p> <section id="CD008190-sec-0081"> <h6 class="title">a. Forced expiratory volume in one second (FEV<sub>1</sub>) (L) </h6> <p>None of the trials reported any change in FEV<sub>1</sub> (L). </p> </section> <section id="CD008190-sec-0082"> <h6 class="title">b. FEV<sub>1</sub> % predicted </h6> <p><a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a> (17 participants) reported an improvement in FEV<sub>1</sub> % predicted graphically at two, three, and six months in the MA treatment group (P &lt; 0.04) and also graphically at one month with no significant difference between groups; further data were not available for analysis in this review. The variation of the change in FEV<sub>1</sub> % predicted was not reported, but could be read from a graph (<a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>). <a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a> (25 participants) also reported change in FEV<sub>1</sub> % predicted at three months. </p> <p>Combined three‐month data showed little or no difference between groups in change in FEV<sub>1</sub> % predicted (MD 4.26, 95% CI −5.45 to 13.97; P = 0.39; 2 trials; 42 participants; low‐certainty evidence; <a href="./references#CD008190-fig-0008" title="">Analysis 1.5</a>). Data at six months from the <a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a> trial alone (17 participants) also showed little or no difference between groups in FEV<sub>1</sub> % predicted (MD 5.64, 95% CI −4.43 to 15.71; P = 0.27; low‐certainty evidence; <a href="./references#CD008190-fig-0008" title="">Analysis 1.5</a>). </p> <p><a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a> (16 participants) did not report means or SDs for the difference between baseline and follow‐up. The trial reported there were no significant differences in spirometric measures, but no FEV<sub>1</sub> % predicted values at 12 weeks were stipulated (<a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>). </p> <p><a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a> (12 participants) reported that FEV<sub>1</sub> % predicted increased by 15.3% on average in the MA group (this was not significant) and by 3.8% in the placebo group.  </p> </section> </section> </section> <section id="CD008190-sec-0083"> <h4 class="title">Secondary outcomes</h4> <section id="CD008190-sec-0084"> <h5 class="title">1. Subjective report of anorexia or loss of appetite, or both</h5> <p>The effect of MA and CH compared to placebo on change in anorexia and appetite was reported for both children and adults (<a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>; <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>). </p> <p><a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a> (16 participants in total, 12 participants assessed for this outcome) reported that at three months, five out of five participants in the CH treatment group answering the questionnaire demonstrated increased appetite versus two participants out of seven in the placebo group; this was assessed using part of a brief five‐question questionnaire. After assessment on interview, <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a> (12 participants in total, 11 participants assessed for this outcome) reported that all participants demonstrated an increase in appetite whilst receiving MA. When analysed, the data showed that appetite stimulants may increase appetite (odds ratio 45.25, 95% CI 3.57 to 573.33; 2 trials; 23 participants; low‐certainty evidence; <a href="./references#CD008190-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD008190-sec-0085"> <h5 class="title">2. Quality of life (QoL)</h5> <p>Only <a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a> (16 participants) reported on the effect of CH versus placebo on change in QoL, with less fatigue reported in two participants in the treatment group only. The remaining trials (54 participants) either did not measure or did not report the effect of appetite stimulants compared with placebo on change in QoL (<a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>; <a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>; <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>). </p> </section> <section id="CD008190-sec-0086"> <h5 class="title">3. Dietary intake</h5> <section id="CD008190-sec-0087"> <h6 class="title">a. Energy intake (kcal/day)</h6> <p>Two trials (41 participants) reported the effect of CH versus placebo on energy intake (<a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>; <a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>). Only <a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a> (25 participants) provided analysable data, but did not demonstrate a difference in energy intake between appetite stimulant or placebo (MD 372.12 kcal, 95% CI −630.80 to 1375.04; <a href="./references#CD008190-fig-0010" title="">Analysis 1.7</a>). Mean caloric intake in <a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a> (16 participants) was determined by three‐day food records prior to visits at four weeks and 12 weeks; the investigators reported no differences between groups (<a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>). One paediatric trial (12 participants) reported the effect of MA versus placebo on change in dietary energy and protein intake; investigators calculated the calorific intake from three‐day food records, but intake did not differ between the treatment and placebo groups (<a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>). </p> </section> <section id="CD008190-sec-0088"> <h6 class="title">b. Protein intake (grams of protein/day)</h6> <p>None of the trials reported protein intake results.</p> </section> </section> <section id="CD008190-sec-0089"> <h5 class="title">4. Any adverse events directly related to the intervention</h5> <p>Objective and subjective adverse events were reported for both MA and CH. <a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a> reported that 2 out of 25 participants experienced fatigue and sleepiness, but it was unclear to which groups these participants belonged. The remaining trials (45 participants) reported adverse effects subjectively, and again without specifying which groups (treatment or placebo) the participants were in. Reported adverse effects included effects on glucose tolerance, decreased cortisol levels, increased insulin levels, insomnia, pulmonary exacerbations, blocked port‐a‐cath, constipation, haemoptysis, and mild transient sedation; see <a href="#CD008190-tbl-0003">Table 2</a>. </p> <div class="table" id="CD008190-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events of appetite stimulants</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Appetite stimulant</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse event reported</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Change in adverse event observed for the treatment group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Change in adverse event observed for the control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Treatment group: frequency of adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control group: frequency of adverse events</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="11" valign="top"> <p><a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="11" valign="top"> <p>Megestrol acetate (Megace)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Glucosuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3. Increased fasting insulin levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4. Hyperactivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5. Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6. Decreased morning cortisol levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7. Increased fasting c‐peptide levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No changes reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8. Increased insulin‐like growth factor‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9. Glucose intolerance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10. Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11. Change in the number of pulmonary exacerbations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="16" valign="top"> <p><a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="16" valign="top"> <p>Megestrol acetate (Megace)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Elevated mean insulin levels         </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3. Elevated liver enzymes                 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4. Pulmonary exacerbation requiring IV ABs  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5. Pulmonary exacerbation requiring aerosolised ABs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6. Transient hyperglycaemia </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7. Moodiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8. Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9. Vomiting </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10. Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11. Elevated haemoglobin A1C levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12. Skin rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13. Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14. Decrease in morning cortisol levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant but reversible decrease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15. Menstrual irregularities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16. Night sweats</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign="top"> <p><a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign="top"> <p>Cyproheptadine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Poorly controlled diabetes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Increased general fatigue </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. At baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>b. At 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Reduced fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. At 4 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3. Days of oral antibiotic use </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4. Days of IV antibiotic use </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5. Transient increase in liver function tests </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/8</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AB: antibiotic<br/>IV: intravenous </p> </div> </div> <p><a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a> (17 participants) reported that MA significantly decreased morning cortisol levels compared to placebo. Furthermore, bone mineral density was reported to have remained stable in the MA‐treated participants over the entire six‐month treatment period, although data were not reported (<a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>). <a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a> (16 participants) reported no significant side effects except for increased general fatigue in the CH group. </p> </section> <section id="CD008190-sec-0090"> <h5 class="title">5. Change in the number of pulmonary exacerbations</h5> <p>Two trials (33 participants) reported on this outcome (<a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>; <a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>). <a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a> (25 participants) reported that in the MA group, six participants required intravenous (IV) antibiotics and four required aerosolised antibiotics (<a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>). <a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a> (16 participants) did not report any significant differences from baseline to week 12 in oral or IV antibiotic use with CH. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008190-sec-0091" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008190-sec-0091"></div> <p>Whilst intuitively an increase in appetite should result in an increase in weight, the precise relationship between the two has not been studied, and is difficult to ascertain for the following reasons. Firstly, there are no good measures of appetite per se; also, the relationship between appetite and weight gain is likely to differ significantly between individuals, and any impact of appetite on weight will be modulated by each individual's eating habits, exercise levels, and metabolic demands. That given, it seems sensible to assume that an increase in appetite should result in weight gain, but further trials are required to delineate this relationship more carefully. </p> <p>We know that lung function is closely associated with nutritional status in CF, and this is an independent predictor of survival (<a href="./references#CD008190-bbs2-0118" title="BellSC , BowermanAR , DaviesCA , CampbellIA , ShaleDJ , ElbornJS . Nutrition in adults with cystic fibrosis. Clinical Nutrition1998;17(5):211-5.">Bell 2008</a>; <a href="./references#CD008190-bbs2-0121" title="BorowitzD . The interrelationship of nutrition and pulmonary function in patients with cystic fibrosis. Current Opinion in Pulmonary Medicine1996;2(6):457-61.">Borowitz 1996</a>; <a href="./references#CD008190-bbs2-0122" title="CoreyM , Mc LaughlanFJ , WilliamsM , LevisonH . A comparison of survival, growth and pulmonary function in patients with CF in Boston and Toronto. Journal of Clinical Epidemiology1998;41(6):583-91.">Corey 1998</a>). However, due to the condition, most people with CF are on a high‐calorie diet to help achieve normal growth and development and maintain good lung function (<a href="./references#CD008190-bbs2-0069" title="NasrSZ , DruryD . Appetite stimulants use in cystic fibrosis. Pediatric Pulmonology2008;43(3):209-19. ">Nasr 2008</a>). Achieving this energy intake from food can be difficult, and is usually not successful (<a href="./references#CD008190-bbs2-0148" title="PoustieVJ , RussellJE , WatlingRM , AshbyD , SmythRL , CALICO Trial Collaborative Group. Oral protein energy supplements for children with cystic fibrosis: CALICO multicentre randomised controlled trial. BMJ2006;332(7542):632-6.">Poustie 2006</a>), but the consequences of inadequate calorie intake (i.e. anorexia) can lead to malnutrition (<a href="./references#CD008190-bbs2-0069" title="NasrSZ , DruryD . Appetite stimulants use in cystic fibrosis. Pediatric Pulmonology2008;43(3):209-19. ">Nasr 2008</a>). </p> <p>Appetite stimulation and increasing food intake may be one way to attempt to address the anorexia. The aim of this review was to ascertain the side effects and effect of appetite stimulants on CF‐anorexia, and hence explore their clinical usefulness. </p> <section id="CD008190-sec-0092"> <h3 class="title" id="CD008190-sec-0092">Summary of main results</h3> <section id="CD008190-sec-0093"> <h4 class="title">Response to treatment</h4> <p>Both MA and CH may slightly improve weight and WAZ in children and adults with CF; increases in both weight and WAZ were seen in the appetite stimulant group compared with the placebo group at three and six months (<a href="./references#CD008190-fig-0004" title="">Analysis 1.1</a>; <a href="./references#CD008190-fig-0005" title="">Analysis 1.2</a>) (low‐certainty evidence). Whilst data showed significant increases in WAZ for both MA and CH separately, there was no difference between the two stimulants, so it cannot be concluded that one stimulant is more effective than the other (<a href="./references#CD008190-fig-0006" title="">Analysis 1.3</a>). However, what constitutes a clinically significant weight gain for children and adults with CF has yet to be directly investigated. Recommendations from the USA aim for a BMI of 22 and 23 in females and males, respectively (<a href="./references#CD008190-bbs2-0153" title="StallingsVA , StarkLJ , RobinsonKA , FeranchakAP , QuintonH . Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. Journal of the American Dietetic Association2008;108(5):832-9.">Stallings 2008</a>). In the UK, it is recommended that weight loss of more than 5% body weight for more than two months duration be prevented, and an adult BMI of less than 19 be avoided (<a href="./references#CD008190-bbs2-0017" title="CF Trust Nutrition Working Group. Appetite. In: Nutritional Management of Cystic Fibrosis: a Consensus Report. Bromley, UK: UK CF Trust, 2002:13. [ISBN 0-9540536-5-6]">CF Trust 2002</a>). In children, USA recommendations state that weight for length should be at least the 50th percentile from birth up to two years, and in children from 2 to 20 years BMI should be at least equal to the 50th percentile (<a href="./references#CD008190-bbs2-0153" title="StallingsVA , StarkLJ , RobinsonKA , FeranchakAP , QuintonH . Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. Journal of the American Dietetic Association2008;108(5):832-9.">Stallings 2008</a>). The definition of significant weight gain is thus not clearly agreed upon. </p> <p>The composition of weight gain is also clinically significant, as correlations have been found between FEV<sub>1</sub> and LBM, which influence skeletal muscle, suggesting an influence of muscle wasting on pulmonary function (<a href="./references#CD008190-bbs2-0154" title="SteinkampG , WiedemannB . Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project. Thorax2002;57:596-601.">Steinkamp 2002</a>). Improving fat‐free mass compared with fat mass may thus well be preferable in order to optimise lung function and body image. However, we found no evidence of a larger increase in FEV<sub>1</sub> (% predicted) in the appetite stimulant group compared with the placebo group at three or six months (<a href="./references#CD008190-fig-0008" title="">Analysis 1.5</a>) (low‐certainty evidence). </p> <p>It is important to highlight that owing to the lack of objective markers for appetite change, the assumption has been made that improved dietary intake and body composition are indicative of an improved appetite. No RCTs have been published assessing appetite using a validated tool. Published trial data did provide some subjective support that MA and CH may improve appetite in children and adults, but the evidence was scant (<a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>). In one trial, during the three months of MA treatment, there was evidence that all children reported increased appetite whilst receiving MA; however, there was no evidence that MA acted to increase calorific intake (<a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>). In a trial of CH, there was limited evidence in children and adults to support an increase in appetite (<a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>). Pooled data from the two trials, which reported an increase in appetite, showed a larger proportion of participants with increased appetite in the appetite stimulant group compared with the control group (<a href="./references#CD008190-fig-0009" title="">Analysis 1.6</a>). However, the certainty of the evidence was low, as only small numbers of participants were included in these trials, and risk of bias due to subjective reporting of appetite change.   </p> <p>Calorific intake was not consistently reported. Only one trial reported analysable data for the change in calorific intake (<a href="./references#CD008190-fig-0010" title="">Analysis 1.7</a>) (<a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>); neither this trial nor the narrative reports from the other trials for this outcome reported a difference between appetite stimulants and placebo (<a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>; <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>). </p> </section> <section id="CD008190-sec-0094"> <h4 class="title">Adverse effects of stimulants</h4> <p>The adverse effects of both MA and CH are not fully determined; the only significant effect reported in the papers was transient mild sedation (<a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>). However unlike MA, which seems to show a propensity to induce glucose dysregulation, CH does not appear to affect glucose tolerance (<a href="#CD008190-tbl-0003">Table 2</a>). </p> </section> <section id="CD008190-sec-0095"> <h4 class="title">Dosage, duration, and timing of appetite stimulants</h4> <p>The data suggest that weight gain may be optimised by treating individuals with 10 mg/kg/day of MA (<a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a>; <a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a>). However, the dosage for CH varied between the other two studies, with one trial administering 4 mg four times daily of CH for three months (<a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a>), and the second trial initially administering 2 mg/mL three times a day for one week, followed by 4 mg/mL three times a day for the remaining 11 weeks (<a href="./references#CD008190-bbs2-0001" title="ACTRN12611000127909. Cyproheptadine as an appetite stimulant in patients with cystic fibrosis and your effect on gain weight. trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000127909 (first received 4 February 2011). [CFGD REGISTER: GN246b] EpifanioM , MarosticaP , MattielloR , FeixL , NejedloR , FischerG , et al. A randomized, double-blind, placebo-controlled trial of cyproheptadine for appetite stimulation in cystic fibrosis. Journal of Pediatrics (Rio J)2012;88(2):155-60. ">Epifanio 2012</a>). The available data from RCTs do not present conclusive evidence for the dose and duration of appetite stimulants in adults and children with anorexia. Longer duration of treatment or the time‐dependency could not be formally assessed due to insufficient data points from the RCTs, and hence also the meta‐analyses. </p> </section> </section> <section id="CD008190-sec-0096"> <h3 class="title" id="CD008190-sec-0096">Overall completeness and applicability of evidence</h3> <p>All included trials directly investigated the impact of the appetite stimulants MA or CH on relevant outcome measures in people with CF. All trials used oral appetite stimulants compared with a placebo. All relevant types of participants, interventions, and outcomes have been investigated. However, there are currently no validated measures of appetite per se available for research purposes in CF, therefore any effects of these appetite stimulants seen in the reported outcome measures are at best surrogate markers of appetite. More research is required to delineate valid measures of appetite in CF, which could then be applied to the outcome measures included in this review, and to the study of appetite stimulants. </p> <p>Hence, within the constraints of the current literature and research tools available, the objectives of this review have been satisfied. The effects of appetite stimulants in CF‐related anorexia and any side effects reported have been rigorously evaluated. </p> <p>Three other appetite stimulants, oxandrolone, dronabinol, and mirtazapine, have been studied in CF. However, trials of these therapies were not included in the review because they did not meet our eligibility criteria. The role of these agents in appetite stimulation in CF deserves further stringent study. </p> <p>Whilst more research is required to delineate the role of appetite stimulants in CF and so to inform clinical practice, the evidence presented within this review suggests that there is a rationale for the short‐term use of MA and CH (six months). Clinicians need to be aware of potential side effects of these agents and monitor individuals accordingly. The clinical benefits need to be balanced, not only against the risks of potential adverse events, but on a case‐by‐case basis. However, there is insufficient evidence at present to justify the use of these agents on a longer‐term basis (over six months). </p> </section> <section id="CD008190-sec-0097"> <h3 class="title" id="CD008190-sec-0097">Quality of the evidence</h3> <p>Trial quality was frequently suboptimal, which could have biased any observed treatment effects, on average, in the direction of overestimating the true treatment effect. </p> <p>There were areas of the reporting within the included trials that would have been greatly improved if the authors had followed the CONSORT reporting guidelines for RCTs, specifically in reporting the details of random sequence generation, allocation concealment, and blinding (<a href="./references#CD008190-bbs2-0143" title="MoherD , SchulzKF , AltmanDG . The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet2001;357(9263):1191-4.">Moher 2001</a>; <a href="./references#CD008190-bbs2-0144" title="MoherD , SchulzKF , AltmanDG . The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Clinical Oral Investigations2003;7(1):2-7.">Moher 2003</a>; <a href="./references#CD008190-bbs2-0145" title="MoherD , AltmanDG , SchulzKF , ElbourneDR . Opportunities and challenges for improving the quality of reporting clinical research: CONSORT and beyond. Canadian Medical Association Journal2004;171(4):349-50.">Moher 2004</a>). We suspect that many of the trials were correctly randomised, but the evidence was not presented in the published papers, and so the risk of bias was marked as unclear. </p> <p>Although there were sufficient data to undertake meta‐analyses for some outcomes, all four included trials reported sufficient detail for a selection of outcomes to be included in the meta‐analyses. A major concern was incomplete reporting of data or selective outcome reporting, or both, with all trials listing outcomes in the methods section of the paper that were not reported on in the results. </p> <p>We assessed the certainty of the evidence supporting the outcomes as low using the GRADE approach (<a href="./full#CD008190-tbl-0001">summary of findings Table 1</a>). We downgraded the certainty of the evidence due to risk of bias (incomplete and selective reporting of outcome data as mentioned above, attrition bias caused by either a proportionately large dropout rate or dropouts due to the intervention and not corrected for in the analyses and the randomisation procedures). In addition, numbers of participants were small and event rates were low, increasing concerns about imprecision. </p> </section> <section id="CD008190-sec-0098"> <h3 class="title" id="CD008190-sec-0098">Potential biases in the review process</h3> <p>The number of trials included in the review precluded an analysis of publication bias, therefore we are unable to comment on this aspect of potential bias. </p> <p>In several trials it was not possible to obtain the effect size and SDs. The outcomes and SDs at baseline and follow‐up were reported accurately, but often the SD of the difference in outcome measure between baseline and follow‐up was not reported and could not be calculated from the reported data. The difference can be calculated from baseline and follow‐up measurements, but the SD of the difference cannot be simply calculated due to within‐participant correlations. It is strongly recommended that outcome differences and SDs of differences be reported in future trials. </p> <p>Trial quality was frequently suboptimal, which could have biased any observed treatment effects on average in the direction of overestimating the true effect. </p> <p>The strengths of the review were the methods used for searching, trial selection, and analysis, which in our opinion did not introduce any bias. </p> </section> <section id="CD008190-sec-0099"> <h3 class="title" id="CD008190-sec-0099">Agreements and disagreements with other studies or reviews</h3> <p>This review concurs with the findings of two other reviews of appetite stimulants (<a href="./references#CD008190-bbs2-0018" title="ChinuckRS , FortnumH , BaldwinDR . Appetite stimulants in cystic fibrosis: a systematic review. Journal of Human Nutrition and Dietetics2007;20(6):526-37. ">Chinuck 2007</a>; <a href="./references#CD008190-bbs2-0069" title="NasrSZ , DruryD . Appetite stimulants use in cystic fibrosis. Pediatric Pulmonology2008;43(3):209-19. ">Nasr 2008</a>), although the evidence was only reviewed systematically by Chinuck and colleagues, whose review served to illuminate the potential role of appetite stimulants in the management of anorexia associated with CF (<a href="./references#CD008190-bbs2-0018" title="ChinuckRS , FortnumH , BaldwinDR . Appetite stimulants in cystic fibrosis: a systematic review. Journal of Human Nutrition and Dietetics2007;20(6):526-37. ">Chinuck 2007</a>). That review concluded that larger RCTs were needed to confirm the safety and validate the efficacy of the use of appetite stimulants in CF, and also highlighted the impossibility of drawing firm long‐term conclusions for the other agents or stimulants given the low numbers of participants in the trials (<a href="./references#CD008190-bbs2-0018" title="ChinuckRS , FortnumH , BaldwinDR . Appetite stimulants in cystic fibrosis: a systematic review. Journal of Human Nutrition and Dietetics2007;20(6):526-37. ">Chinuck 2007</a>). </p> <p>The side effects of adrenal insufficiency, testicular failure, <a href="./references#CD008190-bbs2-0141" title="McKoneEF , TonellMR , AitkenML . Adrenal insufficiency and testicular failure secondary to megesterol acetate therapy in a patient with cystic fibrosis. Pediatric Pulmonology2002;34(5):381-3.">McKone 2002</a>, and bone metabolism, <a href="./references#CD008190-bbs2-0160" title="WermersRA , HurleyDL , KearnsAE . Osteoporosis associated with megesterol acetate. Mayo Clinic Proceedings2004;79(12):1557-61.">Wermers 2004</a>, have been elucidated in the literature, and we would have included these outcomes in our reporting of adverse effects if the included trials had measured and documented these accordingly. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008190-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/urn:x-wiley:14651858:media:CD008190:CD008190-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram (2022 update)." data-id="CD008190-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_n/nCD008190-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_t/tCD008190-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram (2022 update).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/full#CD008190-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_n/nCD008190-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008190-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/urn:x-wiley:14651858:media:CD008190:CD008190-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008190-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_n/nCD008190-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_t/tCD008190-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/full#CD008190-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_n/nCD008190-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008190-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/urn:x-wiley:14651858:media:CD008190:CD008190-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008190-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_n/nCD008190-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_t/tCD008190-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/full#CD008190-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_n/nCD008190-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008190-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/urn:x-wiley:14651858:media:CD008190:CD008190-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Appetite stimulants versus placebo, Outcome 1: Change in weight (kg)" data-id="CD008190-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_n/nCD008190-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_t/tCD008190-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Appetite stimulants versus placebo, Outcome 1: Change in weight (kg)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/references#CD008190-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_n/nCD008190-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008190-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/urn:x-wiley:14651858:media:CD008190:CD008190-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Appetite stimulants versus placebo, Outcome 2: Change in weight z score" data-id="CD008190-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_n/nCD008190-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_t/tCD008190-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Appetite stimulants versus placebo, Outcome 2: Change in weight z score</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/references#CD008190-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_n/nCD008190-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008190-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/urn:x-wiley:14651858:media:CD008190:CD008190-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Appetite stimulants versus placebo, Outcome 3: Change in weight z score at 3 months (subgroup analysis by appetite stimulant)" data-id="CD008190-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_n/nCD008190-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_t/tCD008190-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Appetite stimulants versus placebo, Outcome 3: Change in weight z score at 3 months (subgroup analysis by appetite stimulant) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/references#CD008190-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_n/nCD008190-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008190-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/urn:x-wiley:14651858:media:CD008190:CD008190-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Appetite stimulants versus placebo, Outcome 4: Change in body composition (BMI)" data-id="CD008190-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_n/nCD008190-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_t/tCD008190-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Appetite stimulants versus placebo, Outcome 4: Change in body composition (BMI) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/references#CD008190-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_n/nCD008190-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008190-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/urn:x-wiley:14651858:media:CD008190:CD008190-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Appetite stimulants versus placebo, Outcome 5: Change in FEV1 %" data-id="CD008190-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_n/nCD008190-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_t/tCD008190-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Appetite stimulants versus placebo, Outcome 5: Change in FEV<sub>1</sub> % </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/references#CD008190-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_n/nCD008190-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008190-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/urn:x-wiley:14651858:media:CD008190:CD008190-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Appetite stimulants versus placebo, Outcome 6: Increase in appetite (subjective reporting)" data-id="CD008190-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_n/nCD008190-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_t/tCD008190-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Appetite stimulants versus placebo, Outcome 6: Increase in appetite (subjective reporting) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/references#CD008190-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_n/nCD008190-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008190-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/urn:x-wiley:14651858:media:CD008190:CD008190-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Appetite stimulants versus placebo, Outcome 7: Dietary intake" data-id="CD008190-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_n/nCD008190-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_t/tCD008190-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Appetite stimulants versus placebo, Outcome 7: Dietary intake</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/references#CD008190-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/media/CDSR/CD008190/image_n/nCD008190-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008190-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Appetite stimulants versus placebo for people with cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Appetite stimulants versus placebo for people with cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with cystic fibrosis </p> <p><b>Setting:</b> outpatients </p> <p><b>Intervention:</b> appetite stimulants </p> <p><b>Comparison</b>: placebo<br/>  </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Appetite stimulants</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in weight (kg)</b> </p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in weight ranged from 0.67 kg to 1.3 kg.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in weight (kg) in the intervention group was <b>1.25 kg</b> <b>higher</b> (0.45 higher to 2.05 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>a,b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in weight (kg)</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in weight was 1.5 kg.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in weight (kg) in the intervention group was <b>3.8 kg higher</b> (1.27 to 6.33 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>a,b</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in weight z score</b> </p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in weight z score ranged from −0.05 to 0.07.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in weight z score in the intervention group was <b>0.61 higher</b> (0.29 higher to 0.93 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/>(3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>b,c</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in weight z score</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in weight z score was 0.02.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in weight z score in the intervention group was <b>0.74 higher</b> (0.26 to 1.22 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>a,b</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in FEV<sub>1</sub> % predicted</b> </p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted ranged from −3.7% to −1.81%. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted in the intervention group was <b>4.26% higher</b> (5.45 lower to 13.97 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>a,b</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in FEV<sub>1</sub> % predicted</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted was 0.83. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in FEV<sub>1</sub> % predicted in the intervention group was <b>5.64 higher</b> (4.43 lower to 15.71 higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>a,b</sup> </b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Increase in appetite (subjective reporting)</b> </p> <p>Follow‐up: 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Of the 23 participants responding to the questionnaires, all 10 participants who took appetite stimulants reported a subjective increase in appetite, compared to only 2 out of 13 participants in the placebo group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 45.25</p> <p>(3.57 to 573.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>d,e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The numbers  were too small to calculate the corresponding risk, therefore results have been reported narratively. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>FEV<sub>1</sub> </b> : forced expiratory volume at one second; <b>OR:</b> odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b>: we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty</b>: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> <p><b>Low certainty</b>: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded once due to risk of attrition and reporting bias.<br/><sup>b</sup>Downgraded once for imprecision due to small number of participants.<br/><sup>c</sup>Downgraded once due to risk of attrition and reporting bias as well as unclear risk of selection bias.<br/><sup>d</sup>Downgraded once due to risk of bias within the included trials as follows: one study was at unclear risk of bias for the randomisation process, and both studies were at unclear risk for allocation concealment; one study was at high risk of attrition bias; and both studies were at high risk of reporting bias.<br/><sup>e</sup>Downgraded once for imprecision due to very low participant numbers and low event rates. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Appetite stimulants versus placebo for people with cystic fibrosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/full#CD008190-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008190-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Cochrane risk of bias tool</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Domain</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Description</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Review authors’ judgement</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sequence generation</b> </p> <p><b>(selection bias)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Description of the method used to generate the allocation sequence in sufficient detail to permit an assessment of whether it should produce comparable groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Was the allocation sequence adequately generated?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Allocation concealment</b> </p> <p><b>(selection bias)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Description of the method used to conceal the allocation sequence in sufficient detail to determine whether intervention allocations could have been foreseen in advance of, or during, enrolment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Was allocation adequately concealed?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Blinding of participants, personnel, and outcome assessors</b> </p> <p><b>(performance bias and detection bias)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Description of measures used, if any, to blind study participants, personnel, and outcome assessors from knowledge of which intervention a participant received. Any information relating to whether the intended blinding was effective </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Was knowledge of the allocated intervention adequately prevented during the study?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incomplete outcome data</b> </p> <p><b>(attrition bias)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Description of the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis. Details of whether attrition and exclusions were reported, the numbers in each intervention group (compared with total randomised participants), reasons for attrition/exclusions where reported, and any re‐inclusions in analyses performed by the review authors </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Were incomplete outcome data adequately addressed?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Selective outcome reporting</b> </p> <p><b>(reporting bias)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Details of how the possibility of selective outcome reporting was examined by the review authors, and what was found </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Are reports of the study free of the suggestion of selective outcome reporting?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other potential sources of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any important concerns about bias not addressed in the other risk of bias domains.</p> <p>If particular questions or entries were prespecified in the protocol of the review, responses should be provided for each question or entry. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Did the study appear to be free of other problems that could put it at high risk of bias? </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Cochrane risk of bias tool</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/full#CD008190-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008190-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events of appetite stimulants</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Appetite stimulant</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Adverse event reported</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Change in adverse event observed for the treatment group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Change in adverse event observed for the control group</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Treatment group: frequency of adverse events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control group: frequency of adverse events</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="11" valign="top"> <p><a href="./references#CD008190-bbs2-0004" title="MarchandV , BakerSS , BakerRD . Leptin level in children with cystic fibrosis, effect of megestrol acetate treatment [abstract]. Journal of Pediatric Gastroenterology and Nutrition1999;29:512. MarchandV , BakerSS , StarkTJ , BakerRD . Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2000;31(3):264-9. ">Marchand 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="11" valign="top"> <p>Megestrol acetate (Megace)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Diabetes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Glucosuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3. Increased fasting insulin levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4. Hyperactivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5. Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6. Decreased morning cortisol levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7. Increased fasting c‐peptide levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No changes reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8. Increased insulin‐like growth factor‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9. Glucose intolerance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10. Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11. Change in the number of pulmonary exacerbations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="16" valign="top"> <p><a href="./references#CD008190-bbs2-0002" title="EubanksV , AtchisonJ , AraniR , ClancyJP , SorscherEJ , WooldridgeN , et al. Effects of megestrol acetate on energy intake, weight gain, body composition and resting energy expenditure in cystic fibrosis patients. Pediatric Pulmonology2000;30 Suppl 20:322-3. EubanksV , KoppersmithN , WooldridgeN , ClancyJP , LyreneR , AraniRB , et al. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics2002;140(4):439-44. ">Eubanks 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="16" valign="top"> <p>Megestrol acetate (Megace)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Elevated mean insulin levels         </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3. Elevated liver enzymes                 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4. Pulmonary exacerbation requiring IV ABs  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5. Pulmonary exacerbation requiring aerosolised ABs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6. Transient hyperglycaemia </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7. Moodiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8. Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9. Vomiting </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10. Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11. Elevated haemoglobin A1C levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12. Skin rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13. Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14. Decrease in morning cortisol levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significant but reversible decrease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15. Menstrual irregularities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16. Night sweats</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign="top"> <p><a href="./references#CD008190-bbs2-0003" title="HomnickD , MarksJH , HareKL , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis. Pediatric Pulmonology2005;40(3):251-6. HomnickDN , HomnickBD , BrooksCD , ReevesAJ , HareKL , MarksJH , et al. The use of cyproheptadine as an appetite stimulant in cystic fibrosis patients [abstract]. Pediatric Pulmonology2003;36 Suppl 25:343. HomnickDN , HomnickBD , ReevesAJ , MarksJH , PimentelRS , BonnemaSK . Cyproheptadine is an effective appetite stimulant in cystic fibrosis. Pediatric Pulmonology2004;38(2):129-34. HomnickDN , MarksJH , HareKL , PimentelRS , BonnemaSK . Long-term trial of cyproheptadine as an appetite stimulant in cystic fibrosis [abstract]. Pediatric Pulmonology2004;38 Suppl 27:330. HomnickDN , MarksJH , RubinBK . The effect of a first-generation antihistamine on sputum viscoelasticity in cystic fibrosis. Journal of Aerosol Medicine2007;20(1):45-9. ">Homnick 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="9" valign="top"> <p>Cyproheptadine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Poorly controlled diabetes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Increased general fatigue </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐ </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. At baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>b. At 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Reduced fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>a. At 4 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3. Days of oral antibiotic use </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4. Days of IV antibiotic use </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5. Transient increase in liver function tests </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No difference reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/8</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>AB: antibiotic<br/>IV: intravenous </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse events of appetite stimulants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/full#CD008190-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008190-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Appetite stimulants versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Change in weight (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 At 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.45, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.80 [1.27, 6.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Change in weight z score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 At 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.29, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.26, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Change in weight z score at 3 months (subgroup analysis by appetite stimulant) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Megestrol acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.24, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Cyproheptadine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.21, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Change in body composition (BMI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Change in FEV<sub>1</sub> % <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 At 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.26 [‐5.45, 13.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.64 [‐4.43, 15.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Increase in appetite (subjective reporting) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 At 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>45.25 [3.57, 573.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Dietary intake <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 At 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>372.12 [‐630.80, 1375.04]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Appetite stimulants versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008190.pub3/references#CD008190-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008190.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008190-note-0014">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008190-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008190-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="hu#CD008190-note-0013">Magyar</a> </li> <li class="section-language"> <a class="" href="ko#CD008190-note-0008">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD008190-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD008190-note-0009">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD008190-note-0007">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008190-note-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD008190-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008190\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008190\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008190\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008190\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008190\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008190\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008190\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008190\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008190\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008190\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008190\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008190\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008190\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008190\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008190\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008190\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008190\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008190\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xNbeAU8n&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008190.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008190.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008190.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008190.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008190.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716861174"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008190.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716861178"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008190.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918da9d18c0a1be3',t:'MTc0MDcxNjg2MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 